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Abstract
Skeletal metastasis is a lethal component of many advanced cancers including
prostate, the second most common cancer among men.

Patients whose prostate

cancer is localized and detected early benefit from multiple treatment options ranging
from active surveillance to radiation and surgery, resulting in a 5-year survival rate of
nearly 100%.

Unfortunately, the prognosis and survival for patients with advanced

metastatic disease is much worse due to the highly aggressive nature of the disease
and a paucity of treatment options. Understanding the mechanisms and interactions
that occur between metastatic cancer cells and the bone will enable the future treatment
landscape for bone metastatic prostate cancer to expand, thereby improving patient
outcomes. Our current knowledge of how metastatic prostate cancer cells interact with
the bone is summarized in a model known as the “vicious cycle.”

Numerous

fundamental vicious cycle factors have been identified, including parathyroid hormonerelated protein (PTHrP), while additional elements, such as matrix metalloproteinases
(MMPs), are progressively being discovered and added to the model.
PTHrP is a critical regulator of bone resorption and augments osteolysis in
skeletal malignancies. In Chapter 2, we report that the mature PTHrP1-36 hormone is
processed by MMPs to yield a stable product, PTHrP1-17. PTHrP1-17 retains the ability to
signal through PTH1R to induce calcium flux and ERK phosphorylation but not cyclic
AMP production or CREB phosphorylation.

Notably, PTHrP1-17 promotes osteoblast

migration and mineralization in vitro, and systemic administration of PTHrP1-17
viii

augments ectopic bone formation in vivo. Further, in contrast to PTHrP1-36, PTHrP1-17
does

not

affect

osteoclast

formation/function

in

vitro

or

in

vivo.

Finally,

immunoprecipitation-mass spectrometry analyses using PTHrP1-17-specific antibodies
establish that PTHrP1-17 is indeed generated by cancer cells.

Thus, MMP-directed

processing of PTHrP disables the osteolytic functions of the mature hormone to
promote osteogenesis, indicating important roles for this mechanism in bone remodeling
in normal and disease contexts.
MMPs have traditionally been associated with cancer progression based on their
extracellular matrix degrading activities.

However, it has become evident that their

regulation of non-extracellular matrix substrates can exert both contributive and
protective effects during tumorigenesis. Previous studies of matrix metalloproteinase-3
(MMP-3) have demonstrated tissue dependent pro- and anti-tumorigenic effects, but
despite elevated expression, its roles have not been explored in bone metastatic
prostate cancer.

In Chapter 3, we show that tumor-derived MMP-3 contributes to

prostate tumor growth in bone. In vitro, we observe that silencing MMP-3 reduces
prostate cancer cell proliferation.

Further, we found increased levels of IGFBP3, a

known MMP-3 substrate, and decreased IGF-1R, ERK, and AKT phosphorylation in the
MMP-3 silenced cells.

Notably, we also observe reduced tumor growth and

proliferation in in vivo intratibial models when tumor-derived MMP-3 expression is
silenced. These data suggest that increased MMP-3 expression by prostate cancer
cells contributes to their proliferation in bone by regulating the activity of the IGF/IGF-1R
signaling axis.

ix

Taken together, our studies indicate that MMPs possess important functional
roles in bone metastatic prostate cancer.

We believe that elucidation of these

mechanisms and their contributions to the vicious cycle of bone metastasis will offer
novel opportunities to design effective therapeutic treatment options.

x

Chapter 1. Clinical and Biological Understanding and Study of Bone
Metastatic Prostate Cancers

1.1 Prostate Cancer and Bone Metastasis
Prostate cancer is the second most common cancer in American men with
approximately 1 in 7 men being diagnosed during their lifetimes [1]. With an aging
population, the incidence of prostate cancer is forecasted to continue rising.

The

majority of prostate cancers are adenocarcinomas. These cancers originate from the
prostate epithelia-comprising basal cells or luminal cells. In addition, some prostate
cancers arise from the neuroendocrine cells of the prostate [2].

Though rare,

neuroendocrine prostate cancers are more aggressive and challenging to treat than
adenocarcinomas. It is also possible for one patient to have more than one type of
prostate cancer [2]. Patients whose disease is detected at an early stage benefit from a
range of treatment strategies including radiotherapy and prostatectomy, resulting in 5
year survival rates near 100% [3, 4]. However, the clinical reality is that many men
present with advanced stages of the disease where 5 year survival rates are only 28%
[4]. Currently, the main treatment option for men with metastatic cancer is hormone
therapy. Historic contributions from Charles Huggins and Clarence Hodges in 1941
revealed that prostate cancer progression could be inhibited by removal of androgens
[5].

These early observations paved the way for the development of androgen

___________________________
Portions of this chapter have been previously published (Frieling et al., Cancer Control, 2015 Jan; 22(1):
109-20) and are utilized with permission of the publisher, CCJ (p 147).
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deprivation therapy, either surgically through castration or chemically through the use of
androgen inhibitors, which has remained the standard treatment for men with advanced
disease for the past 70 years. Despite the remarkable initial response to androgen
deprivation for men with advanced disease, it almost invariably progresses to a
castration resistant state within 18-24 months [6].
1.1.1 Castration Resistant Prostate Cancer (CRPC)
Castration resistant prostate cancer (CRPC) is defined by disease progression
that, despite androgen deprivation, is often indicated by rising levels of prostate specific
antigen (PSA), an androgen receptor target [7].

The development of resistance to

hormonal intervention and the causes of disease progression are not fully understood,
though a number of mechanisms have been demonstrated, with the majority focusing
on continued AR activity caused by AR variants. In addition, numerous mechanisms
contributing to tumorigenesis including TMPRSS2/ERG fusion, PTEN mutation and
loss, Nkx3.1 expression loss, and enhanced Egr1 activity have been described [8].
1.1.2 Metastatic Castration Resistant Prostate Cancer (mCRPC)
As the disease progresses, CRPC ultimately advances to metastatic castration
resistant prostate cancer (mCRPC).

Prostate cancer preferentially metastasizes to

bone [9]. As the disease transitions from castration sensitive to castration resistant, the
incidence of bone metastases increases, with more than 90% of mCRPC patients
developing bone lesions [10, 11]. Patients with mCRPC have a poor prognosis and a
predicted survival of less than 2 years from the initial time of diagnosis. Consequently,
mCRPC is responsible for a significant portion of the 30,000 prostate cancer related
deaths every year [1, 12]. Furthermore, symptomatic mCRPC patients are at a high risk
2

for skeletal related events (SRE) including spontaneous fracture, spinal cord
compression, and hypercalcemia that are a source of significant pain and decreased
quality of life [13].

Currently mCRPC is an incurable disease of major clinical

significance.

1.2 Organotropism and Outgrowth of Metastases in Bone
1.2.1 The Metastatic Cascade
Metastasis from the primary site to a secondary site is a multi-step process, with
each step presenting a unique hurdle for the disseminated cells to overcome. This
series of events is termed the metastatic cascade [14]. Although it is technically an
inefficient process with low probability of success, metastasis is a primary cause of
cancer mortality. The process begins with tumor growth at the primary site. As the
primary tumor expands and becomes vascularized, tumor cells begin to locally invade
by adopting a more mesenchymal phenotype and breaching the basement membrane
into the stroma. Following local invasion, tumor cells gain access to the vasculature
and intravasate into the bloodstream or lymphatic system. Although the bloodstream
provides a route by which the disseminated cells can travel to secondary organs and
tissues, shear forces and susceptibility to anoikis create a hostile environment for
circulating tumor cells. Tumor cells that survive in circulation will become lodged in
capillaries, frequently in the lung, due to being significantly larger than erythrocytes and
other blood cells (most cancer cells are >20 µm in diameter whereas the capillaries are
3 µm to 8 µm in inner diameter). Although it is poorly understood, some of these cells
reach other organs such as the bone, with certain cancers metastasizing to secondary
3

sites more frequently than others [15]. To establish at the secondary site, the tumor
cells must extravasate and form micrometastases.

Micrometastases can be widely

distributed, and recent evidence suggests that they occur early in tumor progression but
may remain clinically undetectable [16].

Colonization and outgrowth of clinically

detectable macrometastases is considered the final step in the metastatic cascade
(reviewed by [14]).
1.2.2 What is Bone?
Bone is comprised of osteoblast-derived type I collagen that is mineralized by
deposition of hydroxyapatite, a combination of magnesium, calcium, and phosphate
ions. The resulting extracellular mineralized matrix is an extremely strong substance,
with the collagen fibers imparting a degree of flexibility to avoid brittleness and fracture.
Two major types of ossification (bone production) contribute to building the human
skeleton. Intramembranous ossification and bone development originates from fibrous
membranes and is responsible for producing flat bones like the skull and clavicle
whereas endochondral ossification originates from hyaline cartilage and generates long
bones such as the femur and tibia [17]. There are also two primary types of bone tissue,
both of which are incorporated during intramembranous and endochondral ossification.
Cortical bone (sometimes called compact bone) is dense and primarily structural or
mechanical in nature while trabecular bone (sometimes referred to as cancellous or
spongy bone) is metabolically active and is located within the bone marrow
compartment.
The combination of 206 bones in our skeleton constitutes a framework for the
other organs and tissues that make up the human body. Bone plays an important role
4

in organ protection, provides for the attachment of ligaments and tendons to yield
locomotion, and acts as a reservoir for most of the body’s calcium, magnesium, and
phosphate. The bone marrow is also the primary site for hematopoiesis.
1.2.3 Bone Stroma and Remodeling
Given the crucial functions that the skeleton provides, remodeling and
homeostasis are critical. Bone is continually remodeled at a rate of about ten percent
per year [18]. Bone metabolism is part of routine skeleton maintenance, but the activity
can also occur in response to a fracture or to meet the demands of mechanical loading
and stimuli. Bone remodeling occurs in localized regions called basic multicellular units
(BMU) [19].

Within the BMU exists a remarkable microcosm of specialized cells:

osteoclasts, osteoblasts, and osteocytes.

These cells reside beneath a bone

remodeling compartment (BRC) canopy and must collaborate with each other to
preserve the tightly regulated balance of bone destruction and formation during bone
metabolism.

If the balance is perturbed, the overall health of the skeleton is

compromised and can result in diseases such as osteoporosis, Paget’s disease, or
cancer associated bone destruction/formation observed in bone metastatic carcinomas
like breast and prostate, respectively.
Osteoclasts are the cells responsible for resorption of existing bone tissue.
These cells form when three or more monocytic precursor cells fuse in response to
macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear kappa
B ligand (RANKL) cytokines secreted by neighboring osteoblasts [20].

Mature

osteoclasts are defined as giant, multi-nucleated bone resorbing cells (approximately
50-100 µM in diameter), and express high levels tartrate-resistant acid phosphatase
5

(TRAcP) [21]. Osteoclasts that are recruited to the bone surface polarize to form a
ruffled border, which increases the cytoplasmic interface with the bone, and an F-actin
rich sealing zone. Within the sealing zone, an ATP dependent proton pump creates an
acidic environment, and enzymes including MMPs and cathepsin K are secreted to
facilitate localized degradation of the underlying bone matrix [21, 22]. The bi-products
of degradation include cleaved collagen fragments along with latent growth factors
released from the matrix. The duration of the bone resorption phase is approximately 3
weeks [23].
Osteoblasts function to produce new bone matrix in the areas of previous
resorption.

They are derived from mesenchymal stem cells and differentiate in

response to bone morphogenetic proteins (BMPs), Wnt/β-catenin signaling cues, and
parathyroid hormone-related protein (PTHrP) [24-26].

During bone resorption,

osteoblasts are recruited to the BMU where they secrete type I collagen and other
matrix proteins to form a non-mineralized layer of osteoid, the first step in synthesizing
new bone. As the layers of osteoid accumulate, increased expression of osteopontin is
observed concomitantly with mineralization [25, 27]. Comprising about 90% of adult
bone, type I collagen fibrils contribute to the strength and integrity of the bone.
Complete mineralization occurs over a 3-4 month period [23]. Subsequent to bone
formation, or apposition, some osteoblasts become bone lining cells, where they
acquire a more flattened shape to permanently reside on the bone surface, mostly on
trabeculae. Bone lining cells possess important functions such as controlling calcium
levels, generating signals to osteoclasts, and forming the BRC during remodeling
processes [22, 28]. Other osteoblasts are retained within the bone matrix where they
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terminally differentiate into mechanosensory osteocytes [22].

Osteocytes are

multifunctional cells that constitute up to 95% of all bone cells. Though isolated within
the bone, osteocytes communicate efficiently with osteoblasts and osteoclasts via to a
sophisticated network of canaliculi.

This network allows osteocytes to serve as

sentinels of the bone, detecting fractures or changes in mechanical loading to regulate
bone metabolism. As the skeleton ages, there is an increase in osteocyte apoptosis,
possibly induced by hypermineralization of the perilacunar matrix, leading fewer viable
osteocytes. This reduction in viable osteocytes is believed to contribute to age-related
skeletal disorders such as osteoporosis [29].
1.2.4 Osteotropism
An unsolved question surrounding metastasis is why prostate cancer has such a
predilection for the bone microenvironment. More than a century ago, Stephen Paget
formulated the “seed and soil” hypothesis to address this question based on his studies
of breast cancer patient case histories [30]. The hypothesis suggested that metastasis
requires “fertile soil” for outgrowth and that metastasis is a challenging process that
begins long before the “seed” meets the “soil.” Paget’s hypothesis was challenged by
James Ewing in the 1920s, proposing that metastasis was instead dependent on
anatomy, vasculature, and lymphatics [31]. Metastasis by anatomy would become the
accepted model until the 1970s when modern experiments rekindled interest in the
“seed and soil” hypothesis, notably observations that circulating tumor cells reach the
vasculature of all organs, but only certain organs are receptive for metastasis [14, 32].
In reality, prostate to bone metastasis occurs by a blend of both hypotheses,
metastasizing first to the pelvic lymph node and then to sites in the bone including iliac
7

crests, sacrum wings, L1-L5 vertebrae, T8-T12 vertebrae, ribs, manubrium, humeral
heads, and femoral necks [33]. While 15-30% of prostate to bone metastases are due
to cells traveling through the Batson’s plexus to the lumbar spine, it is clear that
molecular factors such as chemokines and integrins underpin the propensity for
prostate cancer cells to metastasize to the skeleton [13].
1.2.5 Osteomimicry
A recurring theme in bone metastasis is the hijacking of normal bone mechanisms
by tumor cells. The concept of “osteomimicry” is one where bone metastatic prostate
cells acquire the ability to produce proteins that are normally restricted to bone cells,
such as osteoblasts, in order to survive and proliferate in the otherwise restrictive bone
microenvironment [34]. A number of genes normally expressed in bone have been
detected in prostate cells including osteocalcin, osteopontin, bone sialoprotein,
osteonectin, RANK, RANKL, and PTHrP [34-37]. Interestingly, the expression of these
genes seems to be associated with the metastatic capacity of the cells. Studies in both
PC3 and LNCaP have shown that osteonectin expression is highest in more invasive
and

metastatic

sublines

including

the

LNCaP

metastatic

variant,

C4-2B.

Immunohistochemical analyses of patient-derived specimens support these findings,
indicating that osteonectin protein levels were elevated in metastatic foci from bone
compared to soft tissue prostate metastases including the bladder and liver [35]. In
addition to changes in gene expression, prostate tumor cells may adopt biological
activities specific to bone cells. In vitro studies indicate that human C4-2B prostate
tumor cells are capable of depositing hydroxyapatite and contributing to mineralization,
a common feature of the sclerotic lesions observed in vivo [36].
8

1.2.6 Understanding the Tumor Microenvironment
1.2.6.1 Pre-Metastatic Niche and Exosomes
Primary tumor derived factors have been implicated in the development of premetastatic niches in distant organs [38]. Through a series of in vivo experiments, it was
illustrated that conditioned media derived from highly metastatic cancer cell lines such
as B-16 melanoma cell lines could stimulate the mobilization of bone marrow derived
VEGFR-1+ VLA4+ Id3+ hematopoietic precursor cells (HPCs) from the bone marrow to
developing pre-metastatic niche sites including lung, liver, spleen, kidney, and testis
[38].

Recently, cancer derived exosomes have been implicated as the mechanism

facilitating long distance tumor-stroma interactions and initiating the pre-metastatic
niche [39]. Exosomes are a micro-vesicle measuring 30-100nm and known to carry a
variety of cargo including functional proteins, mRNA, and miRNA [40]. In the context of
pre-metastatic niche formation, B16-F10 derived exosomes have been labeled and
shown to “home” to common sites of melanoma metastasis. Further, in the premetastatic niche, exosomes can educate bone marrow derived cells to support
metastatic tumor growth via the horizontal transfer of the c-MET protein [41].
Exosome shedding has also been demonstrated in prostate cancer with studies
demonstrating the presence of microvesicles termed “oncosomes” (0.5-5µm) in prostate
cancer conditioned media. Oncosomes contain a variety of signal transduction proteins
including Akt and Src, as well as miRNAs, and can interact with both tumor and stromal
cells to elicit disease promoting responses [42, 43]. Additionally, there is a correlation
between a Gleason score higher than 7 and the number of oncosomes present in
patient plasma [44]. Based on these findings it is plausible that prostate cancer derived
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exosomes can play a role in the formation of pre-metastatic niches in the bone
microenvironment, and emerging evidence suggests that prostate cancer cells homing
to the bone microenvironment can occupy the endosteal and/or vascular niches.
1.2.6.2 SDF-1(CXCL12)/CXCR4 and similar signaling axes
Bone is the home of regulatory sites for hematopoietic stem cells (HSCs); these
cells are localized to the vascular (inner bone marrow) and endosteal (outer bone
marrow) niches where they either await hematopoietic demand or reside in a quiescent
state [45]. Disseminated tumor cells (DTCs) have been found in the bone marrow
niches where they either form metastases or remain dormant.

One well defined

signaling axis implicated in metastasis and homing to the niche is that between stromal
cell-derived factor-1 (SDF-1)/C-X-C chemokine motif 12 (CXCL12) and its receptor C-XC chemokine receptor type 4 (CXCR4), a system normally utilized by HSCs [46].
CXCL12 expression is increased in the pre-metastatic niche, and studies in prostate
cancer have demonstrated that tumor cells with high bone homing capacity express
CXCR4 and CXCR7 to parasitize the HSC niche (Figure 1A-B).

Furthermore, the

expression of CXCR4 and CXCR7 correlates with poor prognosis [38, 47, 48].
Additional axes including MCP-1/CCR2 and CXCL16/CXCR6 have also been found to
contribute to prostate cancer progression through increases in proliferation, migration,
and invasion [49, 50].
1.2.7 The Vicious Cycle
Once the tumor cells have disseminated and homed to the bone, their survival
and growth are largely dependent on a permissive microenvironment. Exosomes and
other signaling cues from the primary tumor can help “prepare the soil” prior to
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colonizing the bone, however metastatic tumor cells can also directly impact the bone
stroma to facilitate invasion and proliferation via the secretion of various growth factors,
cytokines, and hormones. In turn, osteoblasts and osteoclasts can interact with the
tumor cells. These interactions between the tumor cells, osteoblasts, and osteoclasts
are summarized in a classic mechanism called the “vicious cycle.”
1.2.7.1 Classical Explanation of Tumor-Bone Cellular Interactions
Prostate to bone metastases are characterized by areas of mixed osteogenesis
and osteolysis that give rise to painful lesions [51]. Numerous factors including PTHrP,
IL-1, IL-6, and IL-11 are highly expressed by tumor cells and have been shown to
interact with osteoblasts.

Aside from their osteogenic activities, osteoblasts are

stimulated by these tumor-derived factors to produce the cytokine RANKL. It is well
known that RANKL is a crucial molecule for osteoclast differentiation and therefore
contributes to the extensive bone remodeling seen in skeletal malignancies. Besides
destruction of the bone, osteoclast mediated bone resorption releases a multitude of
bone derived factors such as TGF-β, insulin growth factor (IGF), platelet derived growth
factor (PDGF), and fibroblast growth factor (FGF) from the bone matrix. These factors
are subject to regulation in the local tumor microenvironment where they can provide
positive feedback via interaction with their respective receptors on the surface of tumor
cells. These interactions contribute to tumor cell proliferation and continued production
of tumor derived factors allowing the cycle to repeat [52].
1.2.7.2 Integrating New Discoveries into the Vicious Cycle
The vicious cycle is continually evolving to include additional cell types,
cytokines, proteases, and new therapies (Figure 1-1 C) [53-56]. Several studies from
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our group have shown contributory roles for highly expressed host matrix
metalloproteinases (MMPs) in the vicious cycle, including the regulation of bone-derived
latent TGF-β and VEGF-A bioavailability by MMP-2 and MMP-9, and the generation of a
soluble form of RANKL by MMP-7 which promotes osteoclastogenesis and mammary
tumor induced osteolysis in vivo [57-59]. In recent years, the interactions with immune
cells have become an appreciated component of the metastatic cascade and an integral
part of the vicious cycle. Bone marrow is a reservoir for a wide range of immune cells
including macrophages, myeloid-derived suppressor cells (MDSCs), dendritic cells, and
T-cells. Interestingly, T-cells have been shown to both stimulate and inhibit osteoclast
formation, but the recruitment of T-regs to the bone marrow may actually inhibit
osteoclastogenesis. MDSCs within the tumor-bone microenvironment suppress T-cells,
release angiogenic, tumor promoting factors, and secrete TGF-β to promote tumor
growth [60, 61]. It has also been shown that recruited MDSCs can differentiate into
osteoclasts [62, 63]. Through these mechanisms, MDSCs can play major roles in the
vicious cycle and promote tumor induced bone disease. Similarly, macrophages can
polarize based on cues from the microenvironment leading to anti (M1) and pro (M2)
tumorigenic phenotypes [64]. M2 polarized macrophages have been shown to assist in
immune evasion and tumor promotion by secreting anti-inflammatory cytokines and
proteinases including MMP-9 [64, 65].

1.3 Approved Therapies for Bone Metastatic Prostate Cancer
Despite remaining incurable with most treatment options being palliative, recent
discoveries and improved understanding of the molecular mechanisms underlying
mCRPC have allowed the therapeutic landscape for mCRPC treatment to rapidly
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Figure 1-1. Dormancy and the "Vicious Cycle" of Bone Metastasis
(A) Disseminated tumor cells can home to the vascular niche and cluster on stable endothelium.
Decreased expression of thrombospondin-1 combined with activation of transforming growth factor β and
periostin in areas of “sprouting” vasculature can result in the outgrowth of tumor cells. (B) Cancer cells
may also home to the endosteal niche via mechanisms such as chemokine motif 12/chemokine receptor 4
where they compete with quiescent hematopoietic stem cells for osteoblast interaction. Subsequently, the
cancer cells can be maintained in a dormant state via interactions with GAS6 and ANXA-2 expressing
niche osteoblasts or proliferate into metastases. (C) A “vicious cycle” occurs between tumor cells and
other cells of the bone microenvironment. Factors secreted by the tumor cells act on osteoblasts, leading
to the increased production of additional factors into the microenvironment, providing positive feedback to
the cancer cells. Matrix metalloproteinases 2, 7, and 9 contribute to the vicious cycle by regulating factors
such as vascular endothelial growth factor A, RANKL, and transforming growth factor β, whereas myeloidderived suppressor cells contribute by releasing pro-tumorigenic factors, suppressing T-cells, and
differentiating into osteoclasts.

expand. These new therapeutic strategies include both broad spectrum and targeted
therapies that will ultimately have a positive impact on overall survival for these patients
within the next decade (Table 1-1). The expansion began with docetaxel in 2004, which
at the time was the first therapy to provide improved survival to mCRPC patients [66,
67]. However, many patients develop resistance to this chemotherapy. To combat this
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issue, five new agents have received FDA approval to treat mCRPC since April 2010:
abiraterone acetate, enzalutamide, cabazitaxel, radium-223, and sipuleucel-T [68].
Below is a discussion of these newly approved agents that target the cancer and host
compartments.
1.3.1 Hormone Therapies
One of the defining measures of mCRPC is resistance to androgen deprivation
therapy. The mechanism of castration resistance is not fully understood, but significant
inroads have been made. For example, prostate cancer cells circumvent castration by
overexpressing and increasing the sensitivity of the AR to residual androgens, acquiring
AR gene mutations leading to gain of function or promiscuous ligand interactions, splice
variants resulting in constitutive AR activation or ligand independent receptors, and
post-translational modifications affecting the stability, localization, and activity of the
receptor [69].

Alternative methods utilized by prostate cancer cells to synthesize

dihydrotestosterone (DHT) have also been shown to circumvent androgen deprivation
methods [70-72].

Efforts to target these mechanisms have resulted in newly FDA

approved androgen deprivation therapy (ADT) options such as abiraterone acetate that
inhibits the activity of the CYP17A1 enzyme, thereby preventing androgen synthesis.
Abiraterone has been successful in improving the overall survival and radiographic
progression free survival of men with mCRPC [73, 74]. Another therapeutic strategy for
preventing androgen utilization by the mCRPC cells is by targeting the AR directly with
reagents such as flutamide, nilutamide, and bicalutamide. Recently, enzalutamide was
approved for the treatment of mCRPC in a post-docetaxel setting [75, 76].
Enzalutamide has a superior affinity to the AR compared to other AR antagonists and
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works by preventing nuclear translocation of the receptor, DNA binding, and recruitment
of co-activators of the AR to not only increase overall survival but also delay the onset
of SREs [77-79].

Recent results from an ongoing phase III trial demonstrated

impressive activity of enzalutamide in chemotherapy naïve patients, potentially leading
to future FDA approval of enzalutamide for this subset of mCRPC patients
(NCT01212991) [80, 81].
1.3.2 Chemotherapies
In addition to ADT strategies, taxane derived chemotherapies are a mainstay
treatment for mCRPC. Docetaxel has remained the standard therapy for mCRPC since
2004 [66, 67]. Cabazitaxel is a more recent derivative of the taxoid family that has
shown increases in overall survival, improvements in progression free survival, and
improved PSA response rates in men with mCRPC [82, 83]. Cabazitaxel was approved
for the treatment of post-docetaxel mCRPC patients by the FDA in 2010 [84]. Additional
clinical trials studying the effectiveness of cabazitaxel as first-line therapy and in
combination with ADT agents like enzalutamide are ongoing (NCT02254785,
NCT02522715).
1.3.3 Microenvironment Targeted Therapies
Given the heterogeneity of mCRPCs and likelihood of ADT/chemotherapy
resistance, targeting the genetically stable host microenvironments that support the
mCRPC instead of the cancer cells themselves represents an attractive treatment
approach. Immune evasion is a hallmark of cancer progression and the goal of recently
approved sipuleucel-T is to make mCRPCs more visible to cytotoxic T-cells [85, 86]
Sipuleucel-T is an autologous immunotherapy approved for treatment of asymptomatic
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or minimally symptomatic mCRPC due to a lack of evidence showing that it directly
impacts the cancer [87]. Sipuleucel-T harnesses the properties of the patient’s own
immune system by collecting peripheral blood mononuclear cells and activating them ex
vivo by exposure to a fusion protein consisting of prostatic acid phosphatase (PAP) and
GM-CSF with PAP being a protein commonly expressed by prostate cancer cells.
Patients receive three separate infusions of the activated cells at two-week intervals to
generate PAP expressing dendritic cells that in turn activate T-cells to recognize and
eliminate PAP expressing prostate cancer cells [85].

Sipuleucel-T is the only FDA

approved immunotherapy to improve survival in prostate cancer, however increasing
concern over a lack of anti-tumor responses in clinical practice suggests that additional
studies to identify patients best suited for Sipuleucel-T may be needed [88, 89].
The majority of mCRPCs arise in the bone matrix where they induce extensive
bone remodeling by stimulating osteoblasts and osteoclasts. The process not only
promotes the growth of the mCRPCs via the solubilization of bone matrix sequestered
growth factors but also causes the patient significant pain and SREs such as
pathological fracture. Therefore, preventing cancer-bone interaction has been a major
focus for several decades. Bisphosphonates such as zoledronic acid, are reagents that
can “stick” to bones undergoing remodeling and upon resorption by osteoclasts induce
apoptosis thereby limiting the amount of cancer induced bone disease [90]. In the
clinic, zoledronic acid has demonstrated a benefit for mCRPC patients by decreasing
the time to SRE incidence [91]. However, although zoledronic acid lowered disease
morbidity, no increase in overall survival has been demonstrated. Receptor activator of
nuclear kappa B ligand (RANKL) is a molecule that is critical for the maturation and
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activation of bone resorbing osteoclasts. Denosumab is a fully humanized monoclonal
antibody that prevents RANKL interaction with the RANK receptor [92]. For patients
with bone mCRPCs, clinical trials demonstrated a significant delay in the time to first
SRE compared to zoledronic acid [93]. There is additional evidence that Denosumab
may have direct effects on tumor burden, particularly tumor cells expressing the RANKL
receptor, RANK [94, 95]. Further, pre-clinical in vivo animal studies have highlighted
the efficacy of docetaxel/Denosumab combination treatment in increasing median
survival times, suggesting that combinatorial approaches with Denosumab could
significantly enhance the overall survival of men with mCRPC [96].
The most recent agent to receive FDA approval for mCRPC is radium-223 [97].
The bone seeking properties of radium-223 as well as other radiopharmaceuticals make
them particularly useful in the treatment of bone metastases.

Whereas most

radiopharmaceuticals emit beta particles, radium-223 emits alpha particles to deliver
more localized radiation (<100 µm distance) to induce localized cell death via DNA
damage [98]. In a study of men with mCRPC previously treated with radiotherapy,
radium-223 showed improved overall survival, time to PSA progression, and reduced
alkaline phosphatase levels (measure of bone remodeling). In addition, radium-223
delays the time to first SRE [99], whereas previous radiopharmaceuticals used to treat
mCRPC were only effective at reducing pain. Therefore, radium-223 represents an
important step forward for the field [97].
1.3.4 Ongoing Clinical Challenges
Although several new cancer and microenvironment specific therapies are under
development to treat prostate cancers, there are areas for improvement, particularly
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with screening and the detection of metastases. While early detection is clearly the best
scenario for successful treatment, a significant number of men will initially present with
advanced prostate cancer harboring occult metastases. As we learn more about the
disease, additional challenges are also emerging such as the discovery of disseminated
tumor cells (DTCs) that have developed mechanisms to metastasize and remain
dormant in the bone as well as the heterogeneous composition of most cancers.

Table 1-1. Approved Therapies for the Treatment of mCRPC

Drug

Target

Effect

Abiraterone acetate

CYP17A1

Reduces circulating testosterone
levels

Cabazitaxel

Microtubules

Microtubule stabililzation,
interrupts cell cycle

Denosumab

RANKL

Decreases bone resorption

Docetaxel

Microtubules

Microtubule stabilization,
interrupts cell cycle

Enzalutamide

Androgen Receptor

Androgen receptor antagonism,
prevents signaling

Radium-223

Bone

Localized radiation

Sipuleucel-T

Ex vivo activation of peripheral
blood mononuclear cells

T-cell activation

Zoledronic Acid

Osteoclasts

Decreases bone resorption

1.3.4.1 Detection of Bone Metastases
Since prostate to bone metastases are primarily bone forming sclerotic lesions,
bone scanning using technetium-99m-methyl diphosphonate is often used for diagnosis.
Technetium-99m-methyl diphosphonate is particularly useful for detecting osteogenic
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lesions due to the incorporation of the radionuclide tracer into regions of new bone
formation by osteoblasts [100]. MRI and PET/CT are also used for detection. A recent
trial comparing 18F-NaF PET/CT, 18F-FDG PET/CT, MRI, and technetium-99m-methyl
diphosphonate identified strengths for each modality [101].

New approaches of

combining modalities help to compensate for each method’s weaknesses and increase
sensitivity and accuracy. However, the ability to detect occult or micrometastases less
than 5mm remains a limitation for all current methodologies [102].

Ongoing

experimental imaging may yield improved imaging options. One such approach relies
on dynamic contrast-enhanced (DCE) MRI or CT scans to visualize the vasculature of
bone metastases. In addition to detecting metastases, this approach shows promise for
measuring treatment responses before changes in tumor volume are noted [102].
1.3.4.2 Disseminated Tumor Cells and Dormancy
Increasing evidence suggests that tumor cells disseminated from the prostate
localize to the bone marrow niche and displace the resident hematopoietic stem cells
(HSCs), where they either proliferate to form metastases or enter a state of dormancy
[103]. Tumor cell dissemination appears to be an early event in prostate cancer, since
patients who undergo prostatectomy may present with metastases many years later
[104, 105]. DTCs reside in the bone marrow niche where they can remain dormant and
resistant to chemotherapy for long time periods (>10 years) before emerging to form
metastatic outgrowths [104]. Although most prostate cancer patients harbor DTCs, not
all will develop metastases, suggesting that mechanisms exist to maintain DTC
dormancy as well as promote awakening [105].
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Recent work has identified several bone marrow dependent mechanisms as
modulators of prostate cancer DTC dormancy. In the endosteal (outer bone marrow)
niche, osteoblast expression of Annexin II (Anxa2) combined with expression of the
Anxa2 receptor, Anxa2R, by HSCs is important in regulating HSC homing to the niche
(Figure 1-1 A and B).

Interestingly, Anxa2R expression is elevated in metastatic

prostate tumor cells and as such, the Anxa2/Anxa2R axis can be hijacked to promote
the homing of prostate tumor cells to the niche. Interrupting the interaction between
Anxa2 and Anxa2R is sufficient to reduce tumor burden in the niche [106]. Continued
studies have revealed that the ligation of Anxa2 with Anxa2R stimulates expression of
the Axl receptor tyrosine kinase [107]. Axl, along with Tyro3 and Mer, are receptors for
osteoblast expressed Growth arrest-specific 6 (GAS6) [108]. As was the case with
Anxa2/Anxa2R, the GAS6/Axl interaction normally occurs between HSC and
osteoblasts and is one mechanism of controlling HSC dormancy [109]. Interestingly,
engagement of osteoblast expressed GAS6 and tumor cell expressed Axl yields a
similar result including growth arrest and enhanced drug resistance in prostate cancer
cells [107]. Following up on these observations, recently published data show that
these activities may be specific to the Axl receptor compared to other GAS6 receptors,
where a high ratio of Axl to Tyro3 expression encourages maintenance of a dormant
state compared to reducing expression of Axl and increasing expression of Tyro3 which
promoted awakening and outgrowth [108].
Interactions between osteoblasts and tumor cells are also important to DTC
dormancy. Prostate cancer cells that bind with osteoblasts also upregulate expression
of TANK binding kinase 1 (TBK1). In vitro and in vivo knockdown of TBK1 resulted in
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decreased drug resistance, suggesting that TBK1 may also play a role in these
processes [110].

A high p38/ERK ratio has been shown to maintain dormancy of

squamous carcinoma cells derived from bone marrow, however interactions with
microenvironment proteins such as fibrillar collagen can stimulate a switch to high
ERK/p38 ratio and reverses dormancy [111]. Interestingly, bone marrow derived TGFβ2 has been implicated in maintaining dormancy of DTCs by p38 activation, and
inhibiting either TGF-β receptor-1 (TGFBR1) or p38 leads to DTC proliferation and
metastasis [112]. Similarly, bone morphogenetic protein 7 (BMP-7) was recently shown
to trigger prostate cancer DTC dormancy in part by activation of p38 [113]. While much
focus has been placed on the endosteal niche, the vascular niche also has implications
for DTC dormancy.

Using advanced imaging techniques, it has been shown that

dormant DTCs also home to perivascular niches in the bone marrow and lung. These
niches promote dormancy through thrombospondin-1 (TSP-1) expression, but
dormancy is lost in regions of sprouting vasculature, due to a loss of TSP-1 and
activation of TGF-β and periostin [114].

In vivo experiments in mice receiving bone

marrow transplants revealed that fewer HSCs successfully engrafted in tumor bearing
mice, suggesting that the tumor cells occupying the niche outcompete HSCs for
residence. In addition, expansion of the endosteal osteoblast niche with parathyroid
hormone (PTH) promotes metastasis, whereas decreasing the size of the niche using
conditional osteoblast knockout models reduces dissemination [115].

Importantly, it

was demonstrated that tumor cells can be forced out of the niche by using established
HSC mobilization approaches, perhaps offering an opportunity for therapeutic
intervention [115].
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1.3.4.3 Heterogeneity
Cancer cell heterogeneity is a challenging clinical component in many cancers
including prostate cancer [116-118].

Greater heterogeneity not only facilitates the

evolution of cancer’s resistance to treatment but also gives the cancer a number of
phenotypic strategies that allow for growth in a variety of microenvironments such as
the bone.

The question then arises as to how to treat heterogeneous cancers?

Emerging studies suggest that most patients would be best served by therapies tailored
not only towards cancer cells harboring common aberrations but also by therapies
geared towards smaller clonal populations that could ultimately become dominant and
resistant. Current National Comprehensive Cancer Network (NCCN) guidelines provide
recommendations as to how to apply the sequence of existing therapies to mCRPC
patients based on individual patient parameters. Recent studies suggest that altering
the sequence or combination of existing therapies can have a profound impact on
overall survival [119].

In order circumvent costly and time-consuming clinical trials

assessing the combination and sequence alterations of the new line of targeted
therapies currently in clinical trials, alternative approaches are required. The use of
patient derived xenograft (PDX) models has been useful for translational studies in
other diseases such as breast cancer [120]. PDX models are preferable to cell lines or
organoid based models as these are subject to selective pressure during in vitro
culturing and often correlate poorly with clinical outcome.

However, difficulties

encountered with the take rates of prostate cancer xenografts has traditionally resulted
in a lack of available PDX models for prostate cancer research. Recently, a series of 21
prostate cancer PDXs were generated from numerous organ sites including primary,
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adrenal, bladder, lymph node, liver, and bone [121]. These PDXs are serially passaged
in mice and retain key histologic and molecular features of clinical disease. As a result,
a better representation of clinical responses can be obtained. With regards to bone
metastatic prostate cancer, 2 PDXs from bone metastases were established, but these
do not spontaneously metastasize to the bone and varied take rates were observed with
intratibial injections. Those that did successfully grow in bone recapitulated the clinical
scenario by generating metastatic lesions that were osteoblastic, mixed, and/or
osteolytic.

The establishment of multiple prostate cancer PDXs will also make it

possible to conduct “PDX Clinical Trials” which utilize multiple PDXs to test promising
therapies or combinations of therapies in a format similar to a phase II clinical trial [121].
Outside of the wet lab, the integration of in silico computational models and genetic
algorithms with individual patient derived biological data can also lead to the rapid
optimization of therapy choice and sequence as well. Such computational models have
been applied to bone metastatic prostate cancer and have been particularly useful at
evaluating and predicting the responses for both existing and experimental therapies
[56, 122].

1.4 Discussion
While there is emphasis on the need for therapies aimed at initiation of
metastasis or eradication of DTCs, many patients will still present with active
metastases.

Therefore improved therapies for these patients via continued

understanding of the vicious cycle should remain a priority, as the interactions between
tumor and stromal cells in the vicious cycle offer many opportunities to intervene.
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Present therapies like zoledronic acid and Denosumab interfere with the osteolytic
component of the vicious cycle, however there is a lack of therapies to inhibit the unique
osteosclerotic component of prostate to bone metastases.

Many roles for specific

MMPs have also been elucidated in the vicious cycle [53, 58, 59], and the development
of MMP inhibitors with improved specificity is one promising strategy that could be used
to modulate the vicious cycle [123, 124].
From these discoveries, it is also becoming evident that prostate cancer
metastasis is not a linear, stepwise procedure. Defining the mechanisms that control
CRPC metastasis and outgrowth and the mechanisms that lead to the unique
osteogenic lesions can elucidate new therapeutic targets that not only impact the cancer
cells directly but also the processes that facilitate the formation of a pre-metastatic
niche, niche seeding, dormancy, and the vicious cycle [125]. These new discoveries
will ultimately impact how mCRPCs are treated clinically.
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Chapter 2. MMP Processing of PTHrP Yields a Selective Regulator of
Osteogenesis, PTHrP1-17

2.1 Introduction
In addition to elevated risk for spontaneous fractures, intense pain, and
increased morbidity, patients with skeletal malignancy frequently present with humoral
hypercalcemia of malignancy (HHM), a condition resulting in elevated blood calcium
levels due increased osteoclast mediated bone resorption driven by their cancer [126].
The precise mechanisms and factors responsible for HHM have long been topics of
interest for researchers, with multiple hypotheses having been generated over the
years. In 1941, Dr. Fuller Albright posited that parathyroid hormone (PTH) or a factor
similar to PTH might be secreted by tumors to cause the hypercalcemia observed in
cancer patients [127, 128].

Alternative factors such as vitamin D sterols,

prostaglandins, and transforming growth factors (TGFs) were also proposed, but these
have not been consistently observed at increased levels in patients with HHM [129].
Nearly 50 years later, Dr. Albright’s hypothesis was validated with the discovery of
PTHrP [130-132]. In the 30 years since its discovery, our knowledge of PTHrP has
expanded from viewing it as an HHM causing, cancer derived hormone, to a cytokine
expressed in numerous tissues with abundant functions occurring throughout our
lifespans [128].
___________________________
Portions of this chapter have been previously published (Frieling et al., Oncogene, 2017 April 3) and are
utilized with permission of the publisher (p148-149).
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2.1.1 PTHrP in Cancer
Since it was discovered in a cancer setting, a substantial number of studies have
focused on roles for PTHrP in malignancy.

PTHrP is overexpressed in numerous

cancers and involved in several steps of cancer progression [133]. Analyses of PTHrP
expression in breast cancer specimens indicate that 60% of primary breast tumors and
90% of bone metastatic breast cancers express PTHrP, suggesting that it is important
for tumor growth in bone [134, 135]. Breast cancer metastases generate osteolytic
lesions that are a product of increased osteoclast formation and activity. Traditionally,
PTHrP has been associated with driving the osteolytic phenotype by mediating the
expression of RANKL by osteoblasts, which can drive the fusion of osteoclast
precursors into mature bone resorbing osteoclasts via interactions with RANKL [20].
For example, the administration of monoclonal PTHrP neutralizing antibodies in mice
inoculated with MDA-MB-231 cells led to a significant reduction in osteolytic bone
lesions as well as a decrease in tumor size, demonstrating the potent effects of PTHrP
in osteolytic breast cancer bone metastases [136].

Intriguingly, Ras driven PTHrP

overexpression has also been noted in prostate cancers which form predominantly
osteogenic metastatic bone lesions [137]. Despite this key difference, PTHrP has been
shown to be a vital factor in this process as well, where it was shown to contribute to
pathological bone remodeling and facilitate tumor growth in vivo after inoculation of
PTHrP overexpressing ACE-1 prostate cancer cells [138].

The methods by which

PTHrP activity is regulated to contribute to the development of both osteogenic and
osteolytic lesions are not well understood and may be related to the presence of
additional factors, such as Wnts, present in the tumor-bone microenvironment.
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2.1.2 PTHrP in Development and Normal Physiology
While significant attention has been placed on understanding the effects of
PTHrP in the context of skeletal malignancy, it also possesses very important roles
throughout development and during normal physiology. Unlike PTH, whose expression
is restricted to the parathyroid glands, PTHrP is ubiquitously expressed in tissues
including heart, skin, bone marrow, fetal liver, gastric mucosa, adrenal, thyroid, breast,
and parathyroid glands, and it has been shown to signal in paracrine, autocrine, and
intracrine manners [139, 140]. In vivo gene ablation studies resulted in phenotypes that
reveal particular importance for PTHrP in skeletal and mammary gland development.
Systemic deletion of PTHrP (Pthlh-/-) produces a neonatal lethal phenotype, with the
pups dying less than 24 hours after birth due to respiratory failure attributed to defective
rib cage formation [141]. These mice also develop domed skulls, shortened snouts and
mandibles, and short limbs, suggesting special importance in endochondral bone
formation.

Non-skeletal organs and tissues appeared normal [141].

Expression of

PTHrP in chondrocytes alone rescues the phenotype and allows the mice to survive to
4-months [142, 143]. Studying the phenotype of these rescued mice has revealed a
failure of early ductal development and provides evidence of a role for PTHrP in
branching morphogenesis [144]. These mice also display dwarfing and failed tooth
eruption [142, 143, 145].

Consistent with these findings, PTHrP haploinsufficiency

produces mice that appear normal at birth but show low bone mass, decreased
trabecular thickness and connectivity, and increased adiposity as they approach 3
months of age. In accord with these in vivo phenotypes, it has since been established
that PTHrP is critical for regulating growth plate development by controlling the
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proliferation and differentiation of chondrocytes [146].

Additional observations have

shown that the recruitment of bone marrow precursors is compromised and osteoblast
apoptosis is increased in PTHrP heterozygous animal models [26].
Throughout adult life, PTHrP remains an important mediator of skeletal
remodeling. It is important to note that PTHrP has a bimodal effect on the skeleton,
acting primarily on osteoblasts while indirectly influencing osteoclast activity via
cytokines such as RANKL [147]. As a potent mediator of bone metabolism, PTHrP has
been the focus for potential therapeutic agents for disorders such as osteoporosis [128].
These studies have shown that the dosing and level of exposure are critical to the
balance between anabolic and catabolic activity, with intermittent dosing regiments
being key to generating an osteogenic response [148-150].

Recently, an anabolic

PTHrP analog called abaloparatide underwent clinical investigation for osteoporosis,
including via transdermal delivery (NCT01343004, NCT0167462, NCT00542425). The
results of phase III clinical trials showed that treatment of postmenopausal women with
abaloparatide for 24 weeks with 40 or 80 µg/kg/day resulted in increases in bone
mineral density compared to placebo [128, 151, 152].
2.1.3 PTHrP Gene, Protein Structure, and Susceptibility to Proteolysis
Parathyroid hormone-related protein is a member of the parathyroid family of
hormones. The PTHrP gene, PTHLH, is located on the short arm of chromosome 12
whereas PTH is found on chromosome 11, reinforcing the view that PTHrP likely arose
from gene duplication at some point in evolution [129, 133].

The resulting protein is

highly conserved among species, however alternative splicing produces three unique
protein isoforms (139, 141, or 173 amino acids). Alternative splicing is unique to human
28

PTHrP, and certain isoforms appear to be preferentially expressed in specific tissues.
The reasons for this have not been elucidated, however the presence of instability
motifs that vary between the mRNA of the isoforms suggests the possibility of distinct
half-lives and may also facilitate the paracrine/autocrine roles for PTHrP as opposed to
the endocrine activities associated with PTH [133].

Figure 2-1. Comparison of PTHrP and PTH Amino Acid Sequences
Most homology between PTHrP1-36 and PTH1-34 (biologically active forms) is within the N-terminal
residues, where 8 of the first 13 amino acids are common. Despite noteworthy differences within the 1534 sequence, which is involved with receptor ligation, both PTHrP and PTH signal through the same
receptor, PTH1R.

The PTHrP protein shares homology with PTH, primarily in the N-terminal region
where 8 of the first 13 amino acid residues are identical (Figure 2-1). The remainder of
the amino acid sequences show minimal homology, but they share a common G-protein
coupled receptor (GPCR) for signaling, the type I PTH receptor (PTH1R) [129]. Upon
ligation, a series of conformational changes in PTH1R lead to a shift of transmembrane
domain 3 away from transmembrane domain 6, permitting access to the cytoplasmic
loops by G proteins that are associated with the adenylyl cyclase and phospholipase C
pathways [153]. Through these signaling pathways, PTHrP stimulates the accumulation
of intracellular second messengers such as cAMP, DAG, and inositol triphosphate (IP3)
which subsequently leads to activation of protein kinase A (PKA), protein kinase C
(PKC), and release of intracellular Ca2+ respectively (Figure 2-2) [154]. This can have
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further downstream effects including CREB and ERK phosphorylation [128, 155, 156].
Following ligation and signal transduction, the receptor is negatively regulated by
desensitization, internalization, and down-regulation. However, some studies have
demonstrated that internalization may not necessarily terminate signaling as the authors
observed that internalized PTH1R could still regulate cAMP for PTH 1-34, although
PTHrP1-36 was restricted to the cell surface, perhaps offering some degree of regulation
between PTH and PTHrP [157].
Traditionally, most if not all known PTHrP activities have been associated with
PTH1R, and extensive studies have attempted to determine the minimum amino acid
sequence able to stimulate PTH1R. PTHrP binds to the receptor via the “two site
model,” where an interaction between the C-terminal domain of active PTHrP (amino
acids 15-34) and the N-terminal region of the receptor contributes to binding affinity.
Despite differing in amino acid sequences beyond amino acid 13, both PTH and PTHrP
contain a crucial alpha-helical binding motif within the amino acids 15-34 sequence
[158]. The second interaction occurs between the N-terminal domain of PTHrP and the
juxtamembrane region of the PTH1R. This interaction is believed to contribute to the
induction of signaling [159]. Although the C-terminal region of the protein appears to be
important for the “two site model,” [155], multiple studies suggest that it is not a
necessity for PTH1R activation. This is supported by studies showing that both PTH 114 and 1-15 are capable of stimulating cAMP but at doses 5 to 6 orders of magnitude
higher than that of PTH 1-34 [160]. Further studies have pinpointed that residues 1-6
play a critical role in eliciting an adenylyl cyclase response. N-terminal deleted analogs
such as 3-34 or 7-34 bind PTH1R, but these are unable to completely stimulate adenylyl
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cyclase and in some instances may act as competitive PTH1R antagonists [161, 162].
Whereas N-terminal residues are more commonly associated with mediating adenylyl
cyclase/PKA/cAMP signaling, the C-terminal portion of PTH1-34 including 29-32 has
often been associated with mediating PKC [163]. However, modifying the first residue
of PTH led to diminished IP production via PLC, suggesting that PKC activity might also
be dependent to some degree on the N-terminal region of PTH [162].

Figure 2-2. Active PTHrP Signals via PTH1R to Induce Downstream Effects

(A) PTHrP is produced as a 139, 141, or 173 amino acid protein with a 36 amino acid signal peptide
requiring further processing for activation. Amino acids 1-36 constitute active PTHrP which signals
through PTH1R. (B) PTHrP (and PTH) activities are mediated via signaling through a G-protein coupled
receptor called PTH1R. In skeletal tissue, PTH1R is expressed on the surface of osteoblasts, osteocytes,
and chondrocytes. The pathway consists of two signaling arms resulting in the activation of protein
kinase A (PKA) or protein kinase C (PKC).

2.1.4 PTHrP Processing
The PTHrP protein has leader sequence of 36 amino acids (-36 to -1 signal
peptide) utilized for intracellular trafficking and secretion.
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The leader sequence is

typically removed as the nascent peptide enters the rough endoplasmic reticulum [164].
After removal of the leader sequence, the resulting product is considered “pro-PTHrP”
and is subject to further modification by proteolytic cleavage. Multiple predicted monoand multi-basic cleavage sites suggest that much of the protein sequence is highly
susceptible to proteolytic cleavage, and it has long been thought that full length PTHrP
is a precursor protein that gets processed into smaller, active peptides [165].

The

susceptibility to proteolysis may also serve as a mechanism that allows PTHrP to act
locally compared to PTH which predominantly behaves as a hormone.

Peptide

fragments generated by proteolysis have been detected from several scenarios
including bench-top test tube reactions, cell culture conditioned media, and even patient
serum (Table 2-1). However, the functions, mechanisms, and proteases responsible for
the generation of these fragments currently represent a major gap in our knowledge.

2.1.5 Products Generated by PTHrP Proteolysis
Many experts in the field have speculated that the full length PTHrP protein in
fact serves as a pro-hormone that is subject to post-translational proteolytic processing
based on the numerous dibasic residues such as arginines and lysines found in its
sequence [165]. As was noted above, continuous administration of PTHrP1-36 has been
shown to induce systemic osteolysis while intermittent application of the hormone
promotes bone formation [26, 166, 167]. The reason for these differential effects has
been potentially ascribed to the labile nature of mature PTHrP [133], and the generation
of multiple protein products by post-translational proteolysis may contribute to its
numerous biological functions in a diverse range of tissues.
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Table 2-1. Previously Identified PTHrP Cleavage Products
Previous studies have identified multiple PTHrP products resulting from proteolysis, however the activities
of these products and the proteases that generate them are largely unknown.

Fragment

Proteases Involved

Known Activities

Reference

1-23

PSA, Neprilysin

Unknown (Loss of cAMP stimulation)

[168, 169]

1-26

Neprilysin

Unknown

[169]

1-36

Prohormone thiol
protease; Furin;
Others unknown

Mature PTHrP

[170-173]

1-86

Unknown

Osteogenic MSC Differentiation

[174]

12-48

Unknown

Unknown (prognostic marker for bone
metastases in breast cancer)

[175]

38-64

Unknown

Cell growth and lung repair

[176]

38-94

Unknown

Inhibition of breast cancer cell growth and
invasion, promotion of apoptosis

[177, 178]

38-111

Unknown

Unknown

[179]

67-86

Unknown

Inhibition of growth and invasion of breast
cancer cells

[180]

107-111

Unknown

Inhibition of osteoclast resorption

[181]

107-139

Unknown

Inhibition of osteoclast resorption

[182]

2.1.5.1 PTHrP1-36 as the Predominant, Active Protein

Evidence of post-translational PTHrP processing raises questions about what
amino acid sequence range comprises the active species of the protein responsible for
classic PTH1R mediated functions, such as those in bone development. Traditionally it
is thought that PTHrP1-36 represents the mature form of PTHrP, with an arginine residue
at amino acid position 37 serving as the preferred cleavage site [171]. This region is
also relatively homoglogous to PTH (Figure 2-1) [170]. Indeed most of the classic
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biological activities attributed to PTHrP such as regulating osteoblast differentiation [26,
183] and stimulating osteoclast formation through osteoblast secretion of RANKL [20,
26] are recapitulated with this 36 amino acid form (occasionally PTHrP1-34). It has also
been shown that administering PTHrP1-34 to PTHrP heterozygous mice improves the
skeletal deficits associated with this phenotype [26].

Similarly, PTHrP1-36 given by

subcutaneous injection to post-menopausal osteoporotic women in clinical trials yields
anabolic effects demonstrated by increases in bone mineral density after 3 months of
daily treatment [149].

Despite this knowledge, the exact proteases involved in the

generation of PTHrP1-36 have not been defined and could vary depending on tissue.
2.1.5.2 N-terminal Derived Peptides
Numerous peptides besides PTHrP1-36 are generated by both identified and
unidentified proteases. For example, kallikrein3/prostate specific antigen (PSA) has
been shown to generate a PTHrP1-23 peptide from PTHrP1-141 [168]. Studies with the
resulting 23 amino acid protein revealed that PSA cleavage abolishes PTHrP induced
cAMP activity in MC3T3E1 cells, potentially representing a tissue (prostate) specific
mechanism of regulation PTHrP activity. PTHrP1-23/1-26 is also generated by neprilysin,
a membrane bound member of the metalloproteainse family [169].

The fact that

multiple proteases generate the same protein would suggest there is a potential
fundamental role, but further studies are required to identify activity for PTHrP 1-23.
2.1.5.3 C-terminal Derived Peptides
Several mid-region PTHrP products have been detected and studied including
PTHrP38-94, PTHrP38-111, and PTHrP67-86. Roles in regulating cellular behaviors including
growth, invasion, apoptosis have been ascribed to many of these peptides (Table 2-1),
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however to date it is unclear how these fragments are generated. An exciting recent
study has explored the utility of PTHrP12-48 as a prognostic marker for bone metastatic
breast cancer [175]. Using SELDI-TOF MS, the plasma proteome of 36 breast cancer
patients was interrogated and determined that PTHrP 12-48 could identify patients at risk
when combined with serum N-terminal telopeptide (NTX) measurements. It has been
suggested by other researchers that dipeptidyl peptidase (DPP) may be able to cleave
between amino acids 48 and 49 of PTHrP [128], but it is presently unclear which
protease(s) are involved with the generation of PTHrP 12-48, or if this fragment possesses
bioactivity. Regardless, given the painful and devastating clinical manifestation of bone
metastases and the lack of clinically significant cancer and bone biomarkers, this
discovery represents an important step forward in the field.
2.1.5.4 Osteostatin
One of the best studied PTHrP products besides PTHrP 1-36 is osteostatin, a
protein comprised of amino acids 107-139.

Again, the proteases and processes

involved in generating PTHrP107-139 are not known, but studies focused on the activity of
this peptide have consistently reported on its ability to inhibit osteoclast activity both in
vitro and in vivo.

The potent anti-resorptive activity of PTHrP107-139 appears to be

contained within amino acids 107 to 111.

Additional studies focusing on just the

PTHrP107-111 sequence indicate that this product possesses very similar activity to
PTHrP107-139. Treating a neonatal mouse model with PTHrP107-111 in the presence of
PTHrP1-34, which is known to induce bone resorption in this model, demonstrated that
PTHrP107-111 in fact antagonizes the pro-resorptive effect of active PTHrP when
administered daily for either 6 or 16 days [181]. Conversely, there is evidence where
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PTHrP107-111 and PTHrP107-139 stimulate osteoclast like cell formation in an in vitro
assay.

The resulting osteoclasts were tested on dentine slices and shown to be

functional [184].

It is possible that PTHrP107-111 (like PTHrP1-36) could have both

osteogenic and osteolytic activities depending on administration and dosing. Although
experiments using PKA and PKC inhibitors have suggested that osteostatin signals
through PTH1R, a competitive PTH1R antagonist was unable to inhibit the induction of
Ca2+ by osteostatin [184-189].
2.1.6 Proteases Involved in Post-Translational PTHrP Proteolysis
Since several PTHrP peptide products appear to possess their own unique
functions, understanding PTHrP proteolysis could uncover significant new roles in
skeletal physiology and malignancy.

Many questions regarding PTHrP processing

remain unanswered. What are the functions for these peptides? Does the processing
occur intracellularly or extracellularly? Which proteases generate the known fragments,
and which other proteases might be involved in generating as of yet-to-be identified
peptides?
As a part of normal biology, proteases are responsible for processing of proteins
by hydrolysis of peptide bonds. Evolutionarily, proteases are believed to have arisen as
a mechanism to catabolize proteins to facilitate the generation of amino acids [190].
Years of protease research has provided a more complete appreciation of the vast
activities of proteases.

A significant discovery was their ability to regulate protein

activity by activating and/or often generating unique bioactive forms of their substrates
[190, 191]. A total of 588 proteases have been identified in the human degradome, and
these can be classified based on their catalytic mechanisms including: aspartic,
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glutamic, metalloproteases, cysteine, serine, and threonine [192, 193].

Aspartic,

glutamic, and metalloproteases use an activated water molecule as the nucleophile
whereas cysteine, serine, and threonine rely on the specific amino acid for which they
are named in the site of proteolysis [190]. Some of these proteases have been shown
to target PTHrP, while many others are predicted to do so.
2.1.6.1 Pro-Protein Convertases
The proprotein convertase family of serine proteases has been identified as
regulators of multiple proteins including hormones, growth factors, receptors, and
enzymes via their ability to cleave intracellularly. The family consists of nine secretory
serine proteases: proprotein convertase 1 (PC1/3), PC2, furin, PC4, PC5, paired basic
amino acid cleaving enzyme 4 (PACE4), PC7, subtilisin kexin isozyme 1 (SKI-1), and
proprotein convertase subtilisin kexin 9 (PCSK9) [194]. Except for SKI-1 and PCSK9,
all of these enzymes prefer to cleave at basic residues [173], many of which occur
abundantly throughout the PTHrP amino acid sequence, including an abundance of
lysine and arginine residues giving rise to potential cleavage sites such as a triplearginine motif at residues 19-21 [165].
Furin is well known for its roles in processing pro-proteins via the “constitutive
pathway,” the main method by which PTHrP is secreted and has been implicated in the
removal of pre-pro regions of both PTH and PTHrP. The highly conserved Arg-Leu-LysArg sequence that falls between proPTHrP and PTHrP is a recognized furin cleavage
site, and furin is known to generate active PTHrP1-36 [164, 173]. This was observed by
co-expressing human pre-proPTH and either furin, PC1/3, or PC2 in BSC-40 and
GH4C1 cell lines. Of these 3 proteases, furin was the most effective at generating
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active PTHrP [173]. This was also confirmed in assays using partially purified furin and
PC1 [173].

Another study evaluated the relationship between PTHrP and furin by

expressing pro-PTHrP in COS-7 cells with endogenous furin expression. Transfection
of pro-PTHrP alone resulted in high levels of PTHrP being secreted into conditioned cell
culture medium, whereas co-transfection of anti-sense furin cDNA and pro-PTHrP
resulted in a notable decrease [164].

This provides further evidence that furin is

involved in the generation of active PTHrP. Given the ubiquitous tissue distribution and
subcellular localization to the Golgi, furin is likely a key enzyme involved in intracellular
processing and secretion of active PTHrP1-36.
2.1.6.2 Prostate Specific Antigen (PSA) Serine Proteases
Prostate specific antigen (PSA) is well-known for its expression in prostate tissue
where it is found increased in prostate cancer patients and has been widely adopted as
a biomarker since the 1990s [195, 196]. Functional roles for PSA in prostate cancer are
not well understood [197]. The normal physiological function of PSA is to degrade
semenogelin I and II in seminal fluid, however it has been shown to cleave other
substrates including fibronectin and laminin [198]. Cleavage of fibronectin and laminin
have been suggested to promote cell invasion [199], while processing of galectin-3,
nidogen-1, and IGFBP-3 by PSA may contribute to adhesion, proliferation, apoptosis,
and angiogenesis [197, 200-203].
PSA can activate latent TGFβ2 via currently unknown mechanisms, an event that
might contribute to the formation of osteoblastic lesions in prostate cancer [204].
Interestingly, PSA has also been demonstrated to hydrolyze PTHrP. Separate studies
have reported its ability to cleave both PTHrP1-34 and PTHrP1-141 resulting in 1-22/23
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amino acid fragments.

Functional analyses of these fragments suggest that PSA

cleavage may be involved in regulating PTHrP activity since the PSA generated
fragments were unable to stimulate cAMP in vitro [168, 205].
2.1.6.3 Cysteine Proteases
Prohormone thiol protease (PTP) is a potential prohormone processing enzyme
that has been found to be expressed in human PTHrP producing cancer cell lines,
including lung, breast, prostate, and lymphoma [172, 206]. It is therefore conceivable
that PTP might process PTHrP. In vitro experiments using recombinant proPTHrP1-141
show that PTP cleaves at residue 37 to generate active PTHrP 1-36. Interestingly, they
also show that the local PTP-generated PTHrP1-36 was involved in regulating lung
cancer cell growth, and lung cancer cell lines that express little PTHrP do not express
PTP [172]. This also suggests that multiple proteases contribute to generating the
active PTHrP1-36 form and that it may occur differently in specific tissues.
2.1.6.4 Matrix Metalloproteinases
Surprisingly, it is unknown if other proteases commonly found in skeletal tissues,
such as matrix metalloproteinases (MMPs), can process or regulate PTHrP1-36. MMPs
are a large (23 member) family of enzymes that collectively control processing and
turnover of the extracellular matrix (ECM) [207]. Bone is rich in type I collagen, and
MMPs with type I collagenase activity, including MMP-1, -2, -8, -13, -14 and -15, have
reported effects on skeletal development and homeostasis [208, 209]. Further, MMPs
also function as key mediators of cell-cell communication given their ability to control the
bioactivity and/or bioavailability of a wide array of growth factors and cytokines [53,
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210]. This is especially true in the context of skeletal malignancies, where there is the
heightened MMP expression at the tumor-bone interface (Table 2-2) [211-213].

Table 2-2. Elevated MMP Expression in the Tumor-Bone Microenvironment
Laser capture microdissection and microarray analysis were used to investigate the expression of MMPs
in the tumor-bone microenvironment. Compared to normal bone, MMP expression is increased at the
tumor/bone interface [211].
MMP

Percentage Increase at
Tumor/Bone Interface

MMP-13

3403%

MMP-7

1311%

MMP-3

366%

MMP-9

326%

MMP-2

320%

MMP-15

179%

MMP-10

129%

MMP-19

107%

MMP-11

106%

MMP-28

97%

MMP-8

96%

MMP-12

95%

MMP-24

92%

MMP-17

88%

MMP-23

85%

MMP-14

82%

In the bone microenvironment cancers provoke aberrant bone remodeling where
mixed lesions containing areas of extensive bone resorption and/or bone formation
[214]. Primary and metastatic bone cancers have been shown to express PTHrP, which
in turn induces RANKL expression in osteoblasts lining the bone to trigger
osteoclastogenesis [215]. Osteoclasts then resorb the mineralized bone matrix,
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releasing bone sequestered growth factors such as transforming growth factor β (TGFβ)
that promote cancer cell survival [216]. MMPs are key regulators of RANKL and TGFβ
bioavailability [58, 211], and given the enzymatic susceptibility of PTHrP 1-36, we
hypothesized that PTHrP was a substrate of MMPs that are expressed in bone under
normal and pathological conditions. Here we report that MMPs are indeed capable of
rapidly processing PTHrP1-36 to yield unique PTHrP peptides. Moreover, one of the
identified peptides, PTHrP1-17, is stable and retains the ability to stimulate intracellular
calcium flux via PTH1R but does not trigger the production of cAMP.

Additionally,

PTHrP1-17 has robust biological activity, where it selectively directs mesenchymal stem
cell/osteoblast differentiation and osteogenesis without (like PTHrP1-36) affecting
osteoclastogenesis/bone resorption. Collectively these data suggest that MMPs are
important regulators of PTHrP activity in the normal and pathological bone
microenvironment.

2.2 Materials and Methods
2.2.1 Cell Lines and Culture
MC3T3-E1, HEK-293, RAW264.7, and SAOS2 cell lines were purchased from
the American Tissue Culture Collection (ATCC) and grown in media recommended by
the ATCC. PAIII cells [217], C4-2B [218], and PC3-2M cells (Perkin Elmer) were grown
in complete Dulbecco’s Modified Eagle’s Medium supplemented with 10% fetal bovine
serum.

All cell lines were periodically tested for mycoplasma (#CUL001B, R&D

Systems) and short tandem repeat (STR) verified at the Moffitt Clinical Translational
Research Core. Mouse bone marrow stromal cells and co-cultures were isolated from
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the tibias of C57BL/6 mice and cultured as described [219].

For PTH1R shRNA

knockdown (Santa Cruz, sc-40158-V) studies in mouse cells standard lentiviral
transduction protocols were used. Transient transfection (Qiagen, Superfect, 301305)
for forced PTH1R expression studies (Origene #RG212841-Human, MC201102-Mouse)
in HEK-293 cells were conducted according to the manufacturer’s instructions. For
conditioned media collection, cells were incubated in serum free conditions for 3 hours
prior to the addition of a fresh aliquot of serum free media. Conditioned media was then
collected after a further 24 hours of incubation. For MMP inhibition/treatment, the broad
spectrum inhibitor GM6001 (Millipore, #CC1010 at a final concentration of 10 μM) or
recombinant MMP-3 (Millipore, #444217 at a final concentration of 100 ng/ml) were
added during the collection of the conditioned media.
2.2.2 Gene Expression Analyses
RNA was extracted with TRIzol® according to manufacturer’s instructions
(Invitrogen #15596). cDNA reverse transcription was performed using a High Capacity
cDNA Reverse Transcription Kit (Applied Biosystems, #4368813). Concentrations of
cDNA samples were determined by Nanodrop, and equal amounts (100ng per reaction)
used for real time qPCR (RT-qPCR, ABI Prism 7900HT). Primers sequences for genes
of interest are: Mouse PTH1R Forward 5’-AGCCAGACGATGTCTTTACCAA-3’; mouse
PTH1R Reverse 5’-GATGCTG GCGTCCACCCTT-3.’ Human PTH1R Forward 5’AGAGAAGAAGTACCTGTGGGG-3’;

human

GATGATCCACTTTTTGTTCCC-3.’

PTH1R
PTHrP

GCAGTGGAGTGTCCTGGTATTC-3’;

PTHrP

Reverse
Forward
Reverse

5’5’5’-

TTGGATGGACTTGCCCTTGT-3.’ RANKL Forward 5’-ACGCCAACATTTGCTTTCGG42

3’; RANKL Reverse 5’-GACC AGTTTTTCGTGCTCCCT-3.’

OPG Forward 5’-

CCTTGCCCTGACCACTCTTA-3’; OPG Reverse 5’-CCTCACACTCACACACTCGGT-3.’
Osteocalcin Forward 5’-GCAGCTTGGCC CAGACCTA-3’; Osteocalcin Reverse 5’GGGTCAGCAGAGTGAGCAGAA-3.’
ACAGACGAACAACCCAAACT-3’;
GGTTTTTGGTCACGTTCAGT-3.’
18S

Reverse

Type
Type

I
I

Collagen
Collagen

Forward

5’-

Reverse

5’-

18S Forward 5’-GTAACCCGTTGAACCCCATT-3’;

5’-CCATCCAATCGGTAGTAGCG-3.’

GAPDH

Forward

5’-

CCTGCACCACCAACTGCTTA-3’; GAPDH Reverse 5’- CCACGATGCCAAAGTTGTCA3.’ All samples were run in triplicate and normalized to 18S or GAPDH. A panel of 84
osteogenic genes was studied using a mouse specific osteogenesis RT 2 ProfilerTM
Assay (Qiagen, PAMM-026ZA-12). RNA was extracted by Trizol® and subsequently
purified using an RNeasy MinElute Cleanup kit (Qiagen, #74204).

Reverse

transcription was performed using an RT2 First Strand Kit (Qiagen, #330401). PCR
array plates were run on standard qPCR instruments (ABI Prism 7900HT) and analyzed
with online software (http://www.SABiosciences.com/pcrarraydataanalysis.php).

Fold

change for all qPCR experiments was calculated using delta delta CT method [220].
2.2.3 MMP Processing and Identification of Cleavage Sites
MMP cleavage assays used recombinant PTHrP (1-86; Abcam, ab50228). 100ng
of recombinant of PTHrP was incubated for 1 hour in MMP digestion buffer (0.15 M
NaCl, 50 mM Tris pH 7.6) in the presence of 100 ng active MMP-2, -3, -7, -9, or -13
(Millipore). Processing was confirmed by SDS-PAGE Coomassie Brilliant Blue staining
and Western blotting. For N-terminal amino acid sequencing (Pro-Seq, Boxford, MA), 2
μg of PTHrP1-86 was incubated with MMP-3 (100 ng/ml) for 1 hour, separated by SDS43

PAGE, and transferred to polyvinylidine fluoride (PVDF) membranes. Subsequent to
Coomassie staining/destaining, bands of interest were excised, dried, and sequenced.
Matrix assisted laser desorption time-of-flight mass spectrometry (MALDI-TOF MS)
analyses were performed at the Moffitt Proteomics Core. Briefly, peptides from MMP
cleavage reactions were extracted using C18 ZipTips (Millipore ZTC18S096) and dried
in a vacuum concentrator. Samples were resuspended in a mix of 5 µL of aqueous 2%
acetonitrile, 1% acetic acid plus 5 µL of α-cyano-4-hydoxycinnamic acid (CHCA)
dissolved at 5 mg/ml in 50% H2O/50% acetonitrile.
PTHrP1-36 (ProImmune) and the major MMP generated fragments (PTHrP 1-17,
PTHrP18-26 and PTHrP27-36) were synthesized via standard FMOC chemistry
(Symphony, PTI) and characterized as previously described prior to use for in vitro and
in vivo analyses [221].

2.2.4 Immunoblotting and Immunoprecipitation-Mass Spectrometry
Cells were lysed with cold RIPA buffer (150 mM NaCl, 1mM EDTA, 1% Triton X100, 1% sodium deoxycholate, 0.1% SDS, 20 mM Tris, pH 8) containing protease and
phosphatase inhibitors (Thermo Scientific, #78442) using standard procedures. Total
protein concentration was determined using BCA (Pierce, #23225) and 10 μg of protein
loaded in 10% SDS-PAGE gels. Blots were blocked in 5% BSA for 1 hour followed by
primary antibody for phospho-ERK (Cell Signaling Technology #9101; diluted 1:1000 in
blocking solution + 0.1% Tween-20), ERK (Cell Signaling Technology #4695; diluted
1:1000 in blocking solution + 0.1% Tween-20), phospho-CREB (Cell Signaling
Technology #9198, diluted 1:1000 in blocking solution + 0.1% Tween-20), CREB (Cell
Signaling Technology #9197, diluted 1:1000 in blocking solution + 0.1% Tween-20), or
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PTHrP (Santa Cruz sc20728; diluted 1:1000 in blocking solution + 0.1% Tween-20)
overnight at 4°C. The blots were washed 3 x 10 minutes in 1X TBST and incubated
with HRP-conjugated anti-species secondary (Cell Signaling Technology, Rabbit
#7074/Mouse #7076, diluted 1:1000 in blocking solution). Blots were developed using
enhanced chemiluminescence (Pierce 32106) and exposed to film. Actin (Santa Cruz
sc-1615; diluted 1:1000 in blocking solution + 0.1% Tween-20) was used as a loading
control.
Antibodies reactive to PTHrP1-17, but not PTHrP18-26 or PTHrP27-36, were
developed

by
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(https://antibodies.cancer.gov) and evaluated by ELISA and spotting various amounts of
PTHrP peptide (1, 10, 50, and 100ng) onto nitrocellulose membranes. Top candidates
were selected and evaluated by immunoprecipitation mass spectrometry assays.
Conditioned cell culture media were collected from 90% confluent cells and divided into
1 mL aliquots. 1 μg of anti-PTHrP1-17 antibody was added per reaction and incubated for
1 hour at 4°C at which point 15 μL of Protein G beads (Ultralink, Pierce) were added
and incubated at 4ᵒC overnight. Beads were washed 3 times with IP wash buffer (100
mM NaCl 50 mM Tris HCl, 0.1% NP-40), followed by 3 washes with nanopure water (18
M) and pooled. Peptide was eluted from the beads with 0.1% trifluoroacetic acid,
dried, and resuspended in chromatography buffer containing 4 fmol/µL of stable isotope
labeled standard (SIS) PTHrP peptides, which incorporate

13

C615N lysine (residue #13

of PTHrP1-17). Samples were analyzed using liquid chromatography-parallel reaction
monitoring mass spectrometry (LC-PRM; nanoRSLC and QExactive Plus, Thermo
[222]). Raw data were imported into Skyline software (https://skyline.gs.washington.edu
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[223]), and PTHrP peptides were quantified using selected transitions. Quantification of
peak areas for those specific fragment ions was used to determine the ratio of
endogenous PTHrP1-17 to the PTHrP1-17 SIS.
2.2.5 PTH1R Signaling Assays
A cAMP-GloTM Assay (Promega, #V1501) was used to assess cAMP production.
MC3T3 and PTH1R-expressing HEK cells (2.5 x 104 cells/well, 384-well plate) were
treated with varying concentrations of PTHrP peptides (1-100 nM, 15 min) and
luminescence was measured on a Victor plate reader. The forskolin analog NKH 477
(Tocris, 10 µM, 15 min) was used as a positive control for cAMP assays. Calcium flux
was determined by loading cells with Fluo-4 DirectTM calcium reagent + Probenecid
(Invitrogen, #F10471, 1 x 105 cells, 48-well plate) and incubated for 30 minutes at 37°C
followed by 30 minutes at room temperature. Increases in fluorescence were measured
by time-lapse microscopy. Using this approach, the change in fluorescence intensity
over time for individual cells in 3 fields of view per condition was quantified (Definiens)
and graphed.
2.2.6 MTS Proliferation Assay
All cell types were seeded at 5 x 104 cells/well in 96-well plate and treated for 24
hours in 5% serum (MSC, Raw 264.7) or serum free (MC3T3, PAIII, PC3-2M, C4-2B,
SAOS-2) containing media. CellTiter 96 (Promega, #G5421) was used to determine
metabolic activity as a surrogate of proliferation, by measuring absorbance at 490nm.
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2.2.7 Morphology and Migration Assays
For immunofluorescence studies, MC3T3 were seeded at 5 x 10 4 cells per well in
8-well glass chamber slides and treated with 10 nM of PTHrP1-17 or PTHrP1-36 in serum
free media for 1 hour. Cells were fixed with 4% paraformaldehyde for 20 min, washed
3x with PBS, and blocked in antibody diluting buffer (2% BSA, 0.1% Triton x100) for 30
minutes at room temperature. Actin filaments were stained using Alexa Fluor 488Phalloidin for 30 minutes at room temperature (Invitrogen A12379, diluted 1:1000 in
antibody diluting buffer). Images were acquired using an upright Zeiss fluorescent
microscope.
For migration assays, osteoblast (MC3T3) and MSC migration was assessed
using modified Boyden chamber assay. Cells (5.0 x 105) were seeded in the upper
chamber after 24 hour serum starvation. PTHrP peptides (10 nM in serum free media)
were added to the lower chamber and incubated over a 5 hour period at 37°C. Serum
free media and 1% serum media were used as negative and positive controls,
respectively. Chamber filters were excised and migrated cells stained with hematoxylin.
The number of migrated cells was determined by counting 3 random fields at 20x for
each condition in triplicate.
2.2.8 In Vitro Osteoblast and Osteoclast Formation Assays
For osteoblast differentiation studies, mouse MSCs (1.2 x 10 5 cells/well in 24-well
plates) were incubated for 21 days in the presence of PTHrP 1-17 or PTHrP1-36 (10 nM,
replenished every third day). Mouse osteogenic supplement (R&D, CCM009) was used
as a positive control. Cells were fixed with 10% neutral buffered formalin (15 minutes,
room temperature), stained with Alizarin red (2%, pH 4.1-4.3, 45 minutes, room
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temperature in dark), and quantified by measuring absorbance at 405 nm. For
osteoclast formation assays, adherent bone marrow macrophage precursors were
cultured for 3 days in the presence of recombinant M-CSF (Preprotech, 20 ng/mL) then
seeded into 48-well plates (30,000 cells/well). The cultures were expanded for an
additional 2 days at which point PTHrP1-17 or PTHrP1-36 were added (100 nM,
replenished daily). Recombinant RANKL (Oriental Yeast Company, 100 ng/mL) plus MCSF (25 ng/mL) was used as a positive control. After 7 days, cultures were stained for
tartrate-resistant acid phosphatase (TRAcP) positivity using solutions detailed below.
The number of bone-lining, multi-nucleated (>3 nuclei per cell), TRAcP positive
osteoclasts was quantified from multiple sections.
2.2.9 In Vivo Osteoclastogenesis Assays
For in vivo calvarial injection assays, 2 µg of PTHrP1-17 or PTHrP1-36 were
injected subcutaneously every 6 hour for 3 days over the calvaria of 4-6 week old
female SCID-Beige mice as reported [224, 225]. Mice were sacrificed 10 hour after the
final injection and calvariae were harvested. Tissues were fixed overnight in 10%
neutral buffered formalin and high resolution μCT scan analyzed (SCANCO-μCT40) as
described [122]. Subsequent to reconstruction and quantitations, tissues were
decalcified in 14% EDTA, pH 7.4 for 3 days. After processing, specimens were paraffin
embedded and 5 µM sections prepared. The sections were stained with hematoxylin
and eosin to observe gross anatomy and trichrome to measure bone formation. For
TRAcP staining and osteoclast measurements, slides were deparaffinized and
rehydrated to water then incubated in Basic Stock Incubation Medium (112 mM
anhydrous sodium acetate, 49 mM dibasic dehydrate sodium tartrate, 0.28% glacial
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acetic acid) containing 1% Naphthol-Phosphate substrate (2% Napthol AS-BI
Phosphate in 2-Ethoxyethanol) for 1 hour at 37°C. Slides were then transferred to Basic
Stock Incubation Medium containing 250 µL Pararosaniline dye (5% pararosaniline dye
in 2N HCl) and 250 µL of sodium nitrite solution (4% sodium nitrite in distilled water) at
37°C and monitored for development of red stained osteoclasts. After developing, the
slides were rinsed in distilled water and counterstained with Hematoxylin, blued, and
aqueously mounted. The number of multi-nucleated, TRAcP positive osteoclasts were
quantified from multiple tissue sections. Only multinucleated (>3 nuclei per cell) TRAcP
positive cells were counted as osteoclasts.
2.2.10 In Vivo Osteogenesis Assays
For ex vivo calvarial organ cultures, calvariae were isolated from 4 day old Rag2-/neonates and cultured on stainless steel wire mesh platforms in BGJb media containing
0.1% BSA as described [226]. Calvariae were treated with 10 nM of PTHrP1-17 or
PTHrP1-36 for 14 days. Ectopic ossicle formation assays were performed by
subcutaneously implanting Gelfoam sponges loaded with 1 x 106 mouse mesenchymal
stem cells into 6 week old male SCID/Beige mice. After 1 week recovery, daily
subcutaneous injections of PTHrP peptides (40 µg/kg/day) were administered for 3
weeks at which point ossicles were harvested for histology and imaging as described
[227, 228]. Tibias were collected at the same time, fixed overnight, and decalcified in
14% EDTA for 3 weeks. Following processing and embedding, trichrome staining was
used to identify areas of trabecular bone formation (blue/green staining of type I
collagen).

Bone volume to total volume (BV/TV) was calculated by measuring
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trabecular bone volume within a 1.0 mm long area starting 0.5 mm from the growth
plate using ImageJ software [219].

2.3 Results
2.3.1 PTHrP is an MMP Substrate
To test if MMPs process PTHrP, we incubated recombinant PTHrP 1-86 with MMP-3
and assessed immediate (1 hour) cleavage products (Figure 2-3 A and B). N-terminal
amino acid sequencing identified that MMP-3 cleaved recombinant PTHrP to generate
the mature form of the protein, PTHrP1-36 (Figure 2-3 C). However, MALDI-TOF MS
analyses demonstrated that PTHrP1-36 was further cleaved to distinct stable peptide
products, including PTHrP1-17,

18-26

and

27-36

(Figure 2-3 D). Kinetic analyses revealed

that MMP-3 generated these main PTHrP products within 1 hour, and the PTHrP1-17
peptide was detected at timepoints as short as 1 minute, indicating rapid turnover by
MMPs (Figure 2-4, Figure 2-5). We also examined the PTHrP processing activity of
other MMPs present in the bone metastatic prostate cancer microenvironment and
found that MMP-2, -7, -9 and -13 could generate PTHrP fragments, and that all tested,
with the exception of MMP-13, consistently generated PTHrP1-17 (Table 2-3). Thus,
PTHrP is an MMP substrate.
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Figure 2-3. PTHrP is Processed by MMPs
(A and B) Recombinant PTHrP1-86 (100 ng; arrow) was incubated for 1 hour with active MMP-3 (100 ng)
and products analyzed by SDS-PAGE with Coomassie blue staining (A) and immunoblot analysis (B).
Arrowhead indicates cleavage product. Molecular weight markers indicated in kilodaltons (kDa). (C) Nterminal amino acid sequencing revealed that MMP-3 cleaved (dashed arrow) PTHrP1-86 between amino
acids 36 and 37. Arrows illustrate the amino acid sequence on either side of MMP-3 cleavage site. Amino
acid position is indicated by numerical superscript. (D) MALDI TOF/MS analyses established that further
incubation (1 hour) of PTHrP with MMP-3 yields novel, stable PTHrP fragments, PTHrP1-17, PTHrP18-26,
and PTHrP27-36.
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Figure 2-4. Kinetics of MMP-3 Processing of PTHrP1-36
(A) PTHrP1-36 (500 ng) and MMP-3 (100 ng) were added together in reaction buffer in the presence of
EDTA (2 mM) to prevent enzymatic activity. Mass spectrometry at the 0 minute time point shows the
percent intensity (% Intensity) of the PTHrP1-36 peak. M/Z denotes the mass to charge ratio. (B-G) EDTA
was added to separate reactions at indicated time points. (H) Mass spectrum profile of MMP-3 enzyme
(100 ng) and reaction buffer in the absence of PTHrP1-36.
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Figure 2-5. MS/MS of MMP-3 Cleaved PTHrP Peptides
(A-G) The 60 minute PTHrP1-36/MMP-3 reaction was analyzed by MS/MS to identify the amino acid
content of the major remaining PTHrP peaks (B-G). M/Z indicates the mass/charge ratio.

Table 2-3. MMP Generation of PTHrP Cleavage Products

AVSEHQLLHDKGKSIQDLRRRFFLHH

AVSEHQLLHDKGKSIQDLRRRFFLHHLIAE

LRRRFFLHH
LRRRFFLHHLIAE

LIAEIHTAEI

1

36

4258.310838

1

17

1904.982465

X

X

X

X

1

26

3167.708578

X

X

X

X

1

30

3593.956413

X

X

18

26

1281.743954

X

X

18

30

1706.984512

27

36

1109.620101
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MMP
MMP-13

M/Z

MMP-9

AVSEHQLLHDKGKSIQD

End

MMP-7

AVSEHQLLHDKGKSIQDLRRRFFLHHLIAEIHTAEI

Start

MMP-3

PTHrP Protein Sequence

MMP-2

A list of the PTHrP products generated by multiple MMPs over the course of 1 hour. MMPs (100 ng/ml)
were incubated with PTHrP1-36 for 1 hour at 37°C . Reactions were stopped via the addition of EDTA (2
mM). MS/MS analysis identified the major PTHrP products produced by each MMP at this time point.

X
X

X

X
X

X

X

X

X

2.3.2 MMP Generated PTHrP1-17 Has Biological Activity
To test if the MMP generated fragments of PTHrP retained biological activity, the
major MMP generated PTHrP peptides, PTHrP1-17,

18-26,

and

27-36

were synthesized and

assessed for their biological effects on primary mouse mesenchymal stem cells (MSCs)
and osteoblasts, which express and respond to signaling from the PTHrP receptor,
PTH1R (Figure 2-6 A) [147]. Low concentrations (10 nM) of PTHrP1-36 are sufficient to
activate PTH1R and promote ERK phosphorylation in these cell types [155]. Notably,
treatment of MSCs and osteoblasts with 10 nM of PTHrP1-36 or PTHrP1-17, induced ERK
phosphorylation within 5 minutes compared to control or scrambled peptide treated cells
(Figure 2-6 B). Increases in response to PTHrP18-26 and PTHrP27-36 were noted, but
these increases were very subtle and variable in repeated experiments (data not
shown). We next looked at CREB phosphorylation since it is another downstream
target of PTH1R signaling [229]. In contrast to our ERK analyses, we observed that
phosphorylation of CREB was only induced by PTHrP1-36 (Figure 2-6 C).
PTH1R GPCR activation also induces rapid cAMP and calcium flux responses
primarily via Gs and Gq signaling respectively [230]. Again, only the addition of PTHrP136

peptide induced cAMP (Figure 2-6 D), whereas both PTHrP1-36 and PTHrP1-17

triggered increases in calcium flux (Figure 2-6 E).

No effects of the PTHrP18-26 or

PTHrP27-36 MMP generated peptides on signaling were noted. These differential effects
for PTHrP1-17 on calcium flux versus cAMP production were recapitulated in HEK cells
engineered to express the PTH1R receptor (Figure 2-7 A-C). Given the reported roles
of PTHrP3-34 and PTHrP7-34 to act as PTH1R antagonists, we also tested multiple
combinations of MMP-generated peptides in combination with PTHrP1-36 to determine if
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Figure 2-6. PTHrP1-17 Has PTH1R-Dependent Signaling
(A) PTH1R expression in MC3T3 osteoblasts and primary MSCs treated in the absence or presence of
PTHrP1-36 for 24 hour. +ve indicates positive control (primary mouse osteoblasts) while –ve indicates
negative non-template control. Molecular weight markers are illustrated in base pairs (bps). (B and C)
ERK phosphorylation (pERK) and CREB phosphorylation (pCREB) in MC3T3 osteoblasts following
treatment with PTHrP peptides (10nM for 5min in serum free media). S 0 and S10 represent the addition of
serum free and 10% serum, respectively. SCR is scrambled peptide control. (D) cAMP production in
MC3T3 osteoblasts treated with PTHrP peptides (10 nM for 15 minutes). Asterisks denote statistical
significance (*, p<0.05; ***, p<0.001). Forskolin (10 μM for 15 minutes) was used as a positive control
(+ve). (E) Calcium flux analysis in MC3T3 osteoblasts after treatment with PTHrP peptides (10 nM). Left,
representative images illustrate fluorescence activity prior to (0 seconds) and following treatment with
PTHrP peptides (60 seconds). Graphs show increase in fluorescence measured in individual cells
(n=20/group) over time. Arrow on graph indicates the time point at which the PTHrP peptides were
added. (F) Generation of PTH1R knockdown (shPTH1R) MC3T3 clones (A thru E) via shRNA
transduction. Scrambled control clones (shControl) were also selected for analysis. +ve indicates
positive control (primary mouse osteoblasts) while –ve indicates negative non-template control. (G) ERK
phosphorylation in shControl and shPTH1R cells (MC3T3 clone D) in response to PTHrP peptides (10 nM
for 5 minutes). (H) Calcium flux assays were performed in shControl and shPTH1R clones after
treatment with PTHrP1-36 and PTHrP1-17 (10 nM). Left, representative images illustrate fluorescence
activity following addition of PTHrP peptides (60 seconds). Graphs show increase in fluorescence (RFU)
measured in individual cells (n=20/group) over time.
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the peptides might antagonize cAMP induction in these HEK cells. The addition of the
PTHrP1-17, PTHrP18-26, PTHrP27-36, or all three together with PTHrP1-36 did not affect the
induction of cAMP (Figure 2-7 D). To determine if PTHrP1-17 effects were mediated via
PTH1R, we generated multiple MC3T3 osteoblast shControl and shPTH1R clones
(Figure 2-6 F). The ability of PTHrP1-17 and PTHrP1-36 to induce ERK phosphorylation
was abrogated in PTH1R knockdown cells vs. control shRNA (Figure 2-6 G). Further,
calcium flux in response to PTHrP1-17 and PTHrP1-36 was significantly reduced in PTH1R
knockdown cells (Figure 2-6 H). These effects on ERK phosphorylation and calcium
flux were validated with a separate shPTH1R clone (Figure 2-8).

Thus, our data

indicates that PTHrP1-17 has biological activity and activates select arms of PTH1Rdirected signaling circuits.
2.3.3 PTHrP1-17 Promotes MSC/Osteoblast Cell Migration
The biological effects of the MMP generated PTHrP fragments and PTHrP 1-36
were assessed in primary MSCs, MC3T3 osteoblasts, an osteoclast precursor cell line
(RAW 264.7), and multiple cancer cell lines (PAIII, C4-2B, PC3-2M, SAOS-2). There
were no overt effects of these four PTHrP peptides on cell growth (Figure 2-9 A-G), and
treatment of osteoblasts with PTHrP1-17 or PTHrP1-36 did not prevent tumor necrosis
factor-α (TNF-α)-induced cell death (Figure 2-9 H) [231].
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Figure 2-7. PTHrP1-17 Induces Calcium Flux but not cAMP in HEK Expressing PTH1R
(A) HEK293 cells were transfected with PTH1R expression construct. +ve indicates positive control
(primary mouse osteoblasts) while –ve indicates negative non-template control. Molecular weight markers
are illustrated in base pairs (bp). (B) cAMP levels in HEK-PTH1R expressing cells treated with PTHrP
peptides (10 nM for 15 minutes). Asterisks denote statistical significance (*, p<0.05; ***, p<0.001).
Forskolin (10 μM for 15 minutes) was used as a positive control (+ve). (C) Calcium flux analysis in
MC3T3 osteoblasts after treatment with PTHrP or scrambled control peptides (10 nM). Graphs show
increase in fluorescence measured in individual cells (n≥20/group) over time. Arrow on graph indicates
the time point (20 seconds) at which the PTHrP peptides were added. (D) cAMP levels in HEK-PTH1R
expressing cells treated with indicated combinations of PTHrP peptides (10 nM for 15 minutes).

Figure 2-8. PTHrP1-17 Stimulates ERK Phosphorylation and Calcium Flux in MC3T3 Osteoblasts via
PTH1R
(A) ERK phosphorylation in shControl and shPTH1R cells (MC3T3 clone C) in response to PTHrP
peptides (10 nM for 5 minutes). (B) Calcium flux assays were performed in shControl and shPTH1R
clones after treatment with PTHrP1-36 and PTHrP1-17 (10 nM). Left, representative images illustrate
fluorescence activity following addition of PTHrP peptides (60 seconds). Graphs show increase in
fluorescence (RFU) measured in individual cells (n≥20/group) over time. Arrow on graph indicates the
time point (20 seconds) at which the PTHrP peptides were added.

57

Figure 2-9. MMP-3 Generated PTHrP Peptides Do Not Affect Cell Growth or Survival
(A-G) MSC, MC3T3 osteoblasts, RAW 264.7 monocytes, prostate cancer cells lines, PAIII, PC3-2M and
C4-2B and the osteosarcoma cell line SAOS-2 were treated with PTHrP fragments (10 nM for 24 hours)
conditions. MTT assay was used as a readout for cell number. Normal growth media (10% Serum: S 10)
was used as a positive control. (H) MC3T3 osteoblasts were treated with TNFα (5 ng/ml for 48 hours) in
the presence or absence of 10nM PTHrP1-17 and PTHrP1-36. Asterisks denote significance (p<0.05) while
n.s. indicates non-significant differences.

However, in assessing the effects of the PTHrP peptides on MSC and osteoblast
proliferation, treated cells acquired a migratory phenotype, characterized by a more
elongated shape (Figure 2-10 A).

PTHrP has been shown to contribute to the

recruitment of osteoblasts in vivo [26]. In keeping with this observation, both PTHrP1-36
and PTHrP1-17 significantly increased migration of MSCs and MC3T3 cells (Figure 2-10
B). These effects of PTHrP1-17 are PTH1R dependent, as knockdown of PTH1R
abolished PTHrP1-17-induced osteoblast migration (Figure 2-10 C).
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Figure 2-10. PTHrP1-17 Promotes MSC and Osteoblast Migration via PTH1R
(A) Morphology of osteoblasts (MC3T3 cells) following treatment of PTHrP 1-17 or PTHrP1-36 (10 nM for 1
hour) was determined by staining with anti-actin antibody and confocal fluorescence microscopy. (B)
Migration of primary MSCs (left) and osteoblasts (MC3T3, right) treated with PTHrP 1-17 versus PTHrP1-36
(10 nM for 6 hours). (C) The migration of shControl (left) and PTH1R knockdown (right, shPTH1R)
MC3T3 osteoblasts following treatment with PTHrP1-17 versus PTHrP1-36 (10 nM for 5 hours). Cell number
per 20x field in 5 micrographs per condition were counted. Positive control for (B) and (C) was media
containing 1% serum (S1). Asterisk denotes statistical significance (p<0.05); n.s., non-significant
differences.

2.3.4 PTHrP1-17 Promotes MSC/Osteoblast Differentiation
PTHrP1-36 is a potent regulator of osteoclastogenesis and bone resorption, but
intermittent treatment of osteoblasts can promote osteoblast differentiation and bone
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formation [232].

To assess effects of PTHrP1-17 on osteoblast differentiation and

mineralization, primary MSCs derived from FVB mice were treated for 16 days with
PTHrP1-17 or PTHrP1-36 in the presence or absence of osteogenic media. Surprisingly,
treatment with PTHrP1-17 alone was sufficient to promote osteoblast differentiation of
MSCs and significantly enhanced the effects of the osteogenic media as determined by
Alizarin red staining and colorimetric analysis (Figure 2-11 A-B). Consistent with the
ability of PTHrP1-17 to promote mineralization, we also observed that PTHrP 1-17 could
induce the expression of Type I Collagen, a major component of the bone extracellular
matrix (Figure 2-11 C). The induction of an osteogenic gene profile in MSCs by PTHrP 117

was studied further using a RT2 Profiler PCR Array. Here, changes in Gli1 and MMP-

8 gene expression, among others, were noted. Additionally, some genes appear to be
differentially regulated between PTHrP1-17 and PTHrP1-36, suggesting that MMP
cleavage might produce PTHrP fragments, such as PTHrP1-17, that possess unique
bioactivities (Table 2-4). To test if these effects of PTHrP1-17 were manifest in vivo, we
used a murine model of ectopic bone formation [228]. Primary MSCs were loaded onto
Gelfoam scaffolds and implanted subcutaneously. Mice were treated daily with vehicle
control, PTHrP1-17, or PTHrP1-36 (40 μg/kg/day; intermittent treatment regimen for 21
days [233]). High-resolution μCT scans of isolated ossicles revealed bone formation in
the PTHrP1-17 and PTHrP1-36 treated animals (Figure 2-11 D). Analysis of trichrome
stained ossicle sections, which allows for the detection of collagen and bone
(blue/green color), supported μCT scans and demonstrated a significant amount of
osteoid in both PTHrP1-17 and PTHrP1-36 treated cohorts (Figure 2-11 E). Underscoring
this observation, trabecular bone volume measurements of hind limbs revealed
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significantly more bone in the PTHrP1-17 and PTHrP1-36 treated mice compared to
control (Figure 2-12 A and B).

Figure 2-11. PTHrP1-17 Promotes MSC and Osteoblast Differentiation
(A) Alizarin red staining of primary MSCs (n = 3) treated with PTHrP1-17 versus PTHrP1-36 (10 nM every
other day for 16 days) in either normal media or in osteogenic media. (B) Quantitation of alizarin red
intensity in control and osteogenic media (OM) treated cells treated with the indicated PTHrP peptides.
(C) Analysis of Type I Collagen expression in MC3T3 osteoblasts treated with PTHrP 1-17 or PTHrP1-36 (10
nM for 48 hours). RT qPCR was used to quantitate the relative fold change in expression.
(D)
Representative μCT scans of ectopic ossicles in control, PTHrP 1-17 or PTHrP1-36 treated mice (n=3/group,
4 implants/mouse). Scale bars are 1 mm. Dashed box represents area of magnification. (E) Trichrome
stained sections derived from control, PTHrP1-17 or PTHrP1-36 treated mice were quantitated for the
amount of bone matrix (blue-green color). Dashed box represents area of magnification. Asterisks
denote significance (*p<0.05; *** p<0.001); n.s., non-significance.

61

Figure 2-12. PTHrP1-17 Promotes Bone Formation
(A, B). BV/TV analysis of trabecular bone formation in tibias derived from ectopic ossicle bearing mice
(n=3/group) treated with saline (Control), PTHrP1-17 or PTHrP1-36. Dashed box (A) represents area of
magnification. Graph (B) indicates bone volume to tissue volume measurements (BV/TV).

2.3.5 PTHrP1-17 Does Not Affect Osteoclastogenesis and Bone Resorption
PTHrP1-36 promotes bone resorption by inducing the expression of factors such
as RANKL [229, 234]. Treatment of whole bone marrow co-cultures with PTHrP1-36
revealed increased RANKL expression as expected, but this response was not
observed following treatment with PTHrP1-17 (Figure 2-13 A). We also noted that
PTHrP1-36 appeared to suppress the expression of osteoprotegerin (OPG), which
inhibits osteoclastogenesis (Figure 2-13 A). Real time PCR analyses confirmed these
observations and demonstrated PTHrP1-36 significantly enhanced RANKL expression
while suppressing OPG (Figure 2-13 B-C). PTHrP1-17 had no effect on the expression of
either of these genes. Taken together, the ratio of average RANKL:OPG transcripts
was lower in PTHrP1-17 versus PTHrP1-36 treated cells (1.61 vs. 15.03, respectively).
These findings suggest that PTHrP1-17 does not contribute to osteoclastogenesis. To
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test this, we performed in vitro osteoclast formation assays using whole bone marrow
co-cultures. As expected, PTHrP1-36 induced robust osteoclast formation, but

Table 2-4. Changes in Osteogenic Gene Expression in PTHrP1-17 Treated MSCs
Gene
Gli1
Col2a1
Egf
Tnf
Dlx5
Gusb
Csf2
Tgfb3
Col1a1
Bmp4
Flt1
Tgfb2
Anxa5
Runx2
Itga3
Tnfsf11
Ctsk
Cd36
Fgfr2
Tgfbr2
Col3a1
Igf1r
Alpl
Col1a2
Bmpr1a
Bglap
Icam1
Smad1
Col5a1
Fgf2
Pdgfa
Bmp1
Smad4
Tgfb1
Tgfbr3
Twist1
Gapdh
Nfkb1
B2m
Acvr1
Smad2
Sox9
Vegfb
Actb
Itga2b
Tgfbr1
Col4a1
Itgb1

PTHrP1-17

PTHrP1-36

Fold Regulation

Fold Regulation

3.29
2.2
1.74
1.66
1.61
1.44
1.41
1.4
1.38
1.34
1.34
1.33
1.27
1.25
1.2
1.2
1.19
1.14
1.14
1.14
1.13
1.12
1.1
1.1
1.07
1.06
1.06
1.06
1.04
1.04
1.04
1.03
1.02
1.02
1.01
1.01
1.01
-1
-1.01
-1.02
-1.02
-1.02
-1.02
-1.02
-1.03
-1.03
-1.04
-1.04

2.02
1.68
1.39
-1.05
1.62
1.54
-1.25
1.31
1.33
1.35
-1.03
1.12
1.38
1
1.31
1.87
1.31
1.2
1.04
-1.18
-1.15
-1.11
-1.11
1.21
1.03
1.19
1.83
-1.07
-1.07
-1.1
1.29
-1.13
-1.07
1.09
-1.31
1.02
-1.05
-1.06
1.05
-1.24
1.04
1.26
-1.09
-1.11
1.19
-1.13
-1.07
-1.06
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Table 2-4. (continued)
Gene
Sost
Itgav
Hsp90ab1
Bgn
Bmpr2
Smad5
Serpinh1
Chrd
Vdr
Bmp2
Cdh11
Col10a1
Igf1
Mmp2
Fn1
Csf1
Vegfa
Fgfr1
Ihh
Nog
Mmp9
Fgf1
Bmp3
Bmp7
Gdf10
Spp1
Comp
Vcam1
Bmpr1b
Smad3
Bmp6
Phex
Mmp10
Ahsg
Itga2
Mmp8
Sp7
Itgam
Csf3
Col14a1
Bmp5

PTHrP1-17

PTHrP1-36

Fold Regulation

Fold Regulation

-1.04
-1.05
-1.06
-1.08
-1.08
-1.08
-1.09
-1.11
-1.11
-1.12
-1.12
-1.12
-1.13
-1.14
-1.16
-1.18
-1.22
-1.24
-1.25
-1.26
-1.28
-1.29
-1.32
-1.32
-1.32
-1.32
-1.38
-1.43
-1.5
-1.51
-1.68
-1.8
-1.96
-2
-2.04
-2.14
-2.21
-2.29
-2.45
-3.05
-3.41

-1.55
-1.05
-1.1
-1.12
-1.48
1.02
-1.08
-1.39
-1.2
-1.44
-1.32
-1.12
-1.39
-1.17
-1.47
-1.18
-1.09
-1.23
1.16
1.13
1.01
-1.84
1.77
1.16
1.16
-1.16
-2.61
-1.26
-1.78
-1.51
-1.7
-1.53
1.04
1.12
-1.31
-2.64
1.52
2.1
-1.95
-2.04
1.13

PTHrP1-17 had no effect on osteoclastogenesis (Figure 2-13 D-E). To determine if this
differential effect of PTHrP1-17 was also manifest in vivo, a calvarial injection assay was
performed. In this model, repeated injections of PTHrP 1-36 (every 6 hours; continuous
treatment regimen) over the calvaria promotes extensive osteolysis [225].
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Mice

continuously treated with PTHrP1-36 displayed areas of extensive bone resorption while
those injected with PTHrP1-17 did not (Figure 2-13 F). TRAcP staining confirmed that
there were significant increases in bone-lining osteoclasts in the PTHrP1-36 treated mice
compared to PTHrP1-17 and control groups (Figure 2-13 G).

Finally, the differential

effects of PTHrP1-17 and PTHrP1-36 on osteoclast activity were further supported by
neonatal calvaria ex vivo assays.

We found that calvaria treated with PTHrP1-36

displayed significant degradation of the calvaria, and that there was no evidence of
bone formation (Figure 2-14 A). In contrast, PTHrP1-17 treatment significantly increased
bone formation (Figure 2-14 B). Thus, PTHrP1-17 selectively promotes osteogenesis.
2.3.6 PTHrP1-17 is Generated by Cancer Cells
To address if the PTHrP1-17 peptide could be detected in biological samples,
PTHrP1-17-specific antibodies were generated for immunoprecipitation and downstream
mass spectrometry (Figure 2-15 A). The lead antibody, clone 2D11 (CPTC-PTHrP-1),
detects PTHrP1-17 and PTHrP1-36 at concentrations as low as 10ng but did not cross
react with the PTHrP27-36 peptide (Figure 2-15 B). Immunoprecipitation followed by mass
spectrometry (IP-MS) [235, 236] allowed for the detection of, and delineation between,
PTHrP1-17 and PTHrP1-36 in multiple PTHrP peptide mixtures (Figure 2-15 C).
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Figure 2-13. PTHrP1-17 Does Not Stimulate Osteoclastogenesis and Bone Resorption
(A) Expression of RANKL and OPG in response to PTHrP1-17 and PTHrP1-36 treatment (10 nM for 48
o
hours) in primary bone marrow cultures (1 BMC). PTHrP1-36 stimulated MC3T3 osteoblasts were used
as a positive control (+ve), while non-template was used as a negative control (-ve). (B and C) RT-qPCR
analyses of effects of PTHrP1-17 or PTHrP1-36 on RANKL (B) and OPG (C) expression in bone marrow
cultures (n=3/group). (D and E) Bone marrow co-cultures were treated for 5 days with PTHrP1-17 or
PTHrP1-36 (10 nM). Recombinant RANKL was used as a positive control (+ve). The number of TRAcP
positive osteoclasts per field of view (D) were counted in each well (E). (F and G) The number of
multinucleated osteoclasts/μm of bone (arrows, F) was determined in multiple tissue sections derived
from animals in each group (n=3/group) (G). Asterisks denote statistical significance (*, p<0.05; **,
P<0.01); n.s., non-significant values.

Figure 2-14. PTHrP1-17 Increases Bone Formation in Ex Vivo Calvaria Organ Cultures
(A and B) Neonatal ex vivo hemi-calvaria (n=3/group) were treated daily with control media, or media
containing PTHrP1-17 or PTHrP1-36 (10 nM for 14 days). The area of new bone formation (distance
between the solid and dashed line; (A) was measured in multiple sections for each condition (B).
Representative images from each group are illustrated. Asterisk denotes significance (p<0.05); n.s., nonsignificant differences.
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Figure 2-15. MMP Generation of PTHrP1-17 in Cancer Cells
(A) Antibodies were raised against PTHrP1-17 and the ability of isolated clones to detect the peptide was
measured by ELISA. (B) Dot blot titration of clone 2D11 against 100, 50 and 10 ng of PTHrP1-17,
PTHrP27-36 and PTHrP1-36. (C) IP-MS detection of PTHrP1-17 after immunoprecipitation with 2D11 from an
equimolar mixture of PTHrP1-17, PTHrP18-26, PTHrP27-36 and PTHrP1-36 peptides. The peak detected at 25
minute corresponds to PTHrP1-17. (D and E) IP-MS of PTHrP1-17 from the conditioned media of the
prostate cancer cell line, PAIII treated in the absence (D) or presence (E) of the broad spectrum MMP
inhibitor GM6001. (F and G). IP-MS of PTHrP1-17 from the conditioned media of the human
osteosarcoma cell line SAOS-2. SAOS-2 cells were treated in the absence (F) or presence of
recombinant MMP-3 (G). The blue lines in D-G represent endogenous PTHrP1-17 at the +3 charge state.

PTHrP is expressed by a number of cancer cell lines, including those of a
prostate and osteosarcoma origin (Figure 2-16). We collected conditioned media from
PTHrP-expressing PAIII rat prostate adenocarcinoma cells incubated in the presence or
absence of a broad-spectrum MMP inhibitor, GM6001.

IP-MS of PAIII conditioned

media clearly demonstrated the presence of PTHrP1-17 and that MMP inhibition reduced
the amount of this product (Figure 2-15 D and E).
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Figure 2-16. Expression and Quantitation of PTHrP1-17 in Cancer Cells using SIS Peptides
(A) Expression of PTHrP in by the prostate cancer cell line PAIII. MC3T3 osteoblasts were used as a
positive control (+ve), while non-template was used as a negative control (-ve). 18S was used as a
loading control. Molecular weight markers are illustrated in base pairs (bp). (B and C). IP-MS of PTHrP117 from the conditioned media of PAIII cells treated in the absence (D) or presence (E) of the broad
spectrum MMP inhibitor GM6001. Graphs include the SIS1-17 internal standards that allow for the
determination of PTHrP1-17 endogenous levels. For graphs B, C, E and F, the blue line represents
endogenous PTHrP1-17 at the +3 charge state while the green line represents the stable isotope labeled
standard (SIS) PTHrP1-17 peptide at the +3 charge state (20fmol per injection). (D) Expression of PTHrP
in by the osteosarcoma cell line SAOS-2. A549 cells were used as a positive control (+ve), while nontemplate was used as a negative control (-ve). 18S was used as a loading control. Molecular weight
markers are illustrated in base pairs (bp). (E and F). IP-MS of PTHrP1-17 from the conditioned media of
the prostate cancer cell line, PAIII cells were treated in the absence (D) or presence (E) of recombinant
active MMP-3 (100 ng/ml overnight). Graphs include the SIS1-17 internal standard that allowed for the
determination of PTHrP1-17 endogenous levels.
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The incorporation of stable isotope labeled standards (SIS1-17) allowed for the
quantification of peak areas from IP-MS experiments and demonstrated GM6001
treatment reduced the amount of PTHrP1-17 by 77% (PaIII = 0.13, PaIII+GM6001 = 0.03;
Figure 2-16 B and C). Conversely, despite the detection of PTHrP transcripts in SAOS-2

osteosarcoma cells, levels of PTHrP1-17 in SAOS-2 conditioned media were low
compared to those in PAIII (Figure 2-15 F). However, overnight incubation of SAOS-2
cells with recombinant exogenous MMP-3 resulted in the enhanced detection of the
PTHrP1-17 peptide (Figure 2-15 G). Use of SIS1-17 demonstrated that the addition of
MMP-3 increased PTHrP1-17 levels by 400% (SAOS-2 = 0.004, SAOS-2+MMP-3 = 0.03,
Figure 2-15 E and F). These data show that PTHrP1-17 can be biologically generated by
cancer cells and in turn this novel MMP generated product can selectively promote
osteogenesis.

2.4 Discussion
MMPs regulate bone matrix turnover as well as the bioactivity and bioavailability of
non-matrix factors such as RANKL and TGFβ that are important for bone remodeling.
Here we have shown that MMPs also process PTHrP 1-36 to yield a distinct, biologically
active peptide, PTHrP1-17, which can be generated by cancer cells. Notably, PTHrP 1-17
promotes osteogenesis yet has no effect on osteoclast formation and bone resorption.
This suggests that MMP-directed cleavage of PTHrP1-36 is a new means for posttranslationally regulating the potent osteolytic effects of this hormone, which has
important implications for our understanding of bone remodeling and skeletal
malignancies (Figure 2-17).
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Figure 2-17. PTHrP1-17 Working Model in Bone Metastatic Cancer
(A) The initiation of the vicious cycle involves the secretion of PTHrP 1-36 from bone metastatic prostate
cancer cells which leads to the induction of RANKL, osteoclastogenesis and the release of growth factors
from the bone matrix such as TGFβ that enhance tumor survival. MMP expression is also heightened at
the tumor bone interface. (B) Heightened MMP expression leads to the generation of PTHrP1-17 that in
turn can promote osteogenesis while preventing osteoclastogenesis. Further, PTHrP1-17 can promote the
recruitment of MSCs that can contribute to the osteogenic response.

Previous studies have shown that PTHrP1-36 is susceptible to proteolytic
processing, but MMP generated PTHrP1-17 appears to be a distinct product.
PSA/kallikrein-3 and neprilysin have both been shown to generate PTHrP 1-23 [168, 169].
Our mass spectrometry data show that a 1-26 fragment can be generated by MMPs but
that this species is rapidly reduced to PTHrP1-17. Comparative kinetic analyses between
enzymes capable of processing PTHrP1-36 may reveal the dominant protease involved,
but it is likely that spatial and temporal factors dictate which protease controls PTHrP 1-36
cleavage. Further, serine proteases and MMPs may reciprocally activate each other.
For example, PSA can regulate MMP-2 activity while, conversely, MMPs can activate
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kallikreins, suggesting that proteolytic cascades could converge to process PTHrP 1-36
[237, 238]. It is also possible that PTHrP1-36 can induce the expression of MMPs that in
turn process the hormone. For example, PTHrP is known to induce the expression of
MMP-2, -3 and -9 in growth plate chondrocytes [239]; the induction of MMPs by PTHrP136

may result in a feedback loop that dampens osteolytic stimuli once bone resorption

has been initiated. Further, PTHrP has also been shown to induce the expression of
MMP-13 [240], but interestingly, our data show MMP-13 does not yield a PTHrP1-17
fragment, again pointing to distinct roles for specific proteases in regulating PTHrP 1-36
activity.
Adding further complexity to PTHrP regulation, a recent report has demonstrated
that serum levels of PTHrP12-48 are a prognostic marker for bone metastatic breast
cancer [175], indicating that a PTHrP1-11 fragment is also generated.

Our mass

spectrometry analyses show that MMPs do not reduce PTHrP further than PTHrP 1-17,
implying that other proteases must be involved in generating this shorter species [128].
Whether PTHrP1-11 retains biological activity is undetermined, but this is possible given
the importance of the first two N-terminal amino acids in activating PTH1R [128]. Our
studies indicate that PTHrP1-17 retains biological activity and PCR array data specifically
indicate that treating MSCs with PTHrP1-17 induces changes in osteogenic gene
expression similar to PTHrP1-36.

Notably, both Gli1 and MMP-8 expression were

downregulated. Interestingly, Gli1 is a Hedgehog (Hh) signaling transcription factor that
has previously been implicated with the expression and activation of various MMPs
[241-243], and the related Gli2 transcription factor is involved in the expression of
PTHrP [244, 245]. PTHrP1-17 treatment also resulted in decreased expression of bone
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morphogenetic protein 5 (BMP5), while BMPs 1, 2, 3, 5, 6, and 7 remained largely
unchanged. It is unclear why BMP5, which together with other BMPs are involved in
osteogenesis, would be downregulated, however there are reports implicating BMP5 in
osteoclast formation [246]. Given the predominantly osteogenic activities of PTHrP 1-17,
reduced BMP-5 expression may help evade osteoclastogenesis. It is also likely that
some variations in osteogenic gene expression could be a result of the phasic nature of
osteogenic gene expression during osteogenic differentiation [247, 248]. Importantly,
our results also indicate that PTHrP1-17 and PTHrP1-36 induce differential gene
expression. Particularly evident is the PTHrP1-17 induced -2.29 fold decrease in Itgam
expression whereas PTHrP1-36 treatment resulted in a 2.10 fold increase. Itgam codes
for CD11b which has roles in regulating osteoclastogenesis of macrophage/monocyte
lineage precursors [249]. Although CD11b expression from a mesenchymal lineage is
not traditionally associated with osteoclast formation, the formation of osteoclasts is
dependent on activity of mesenchymal lineage cells such as osteoclasts. Decreased
expression of CD11b by MSCs in response to PTHrP1-17 might be one factor
contributing to the reduced osteoclast formation seen in our studies of PTHrP 1-17;
however, these cellular interactions would require further study. Additionally, it is easy
to speculate that additional genes and genetic programs are differentially regulated by
PTHrP1-17 and PTHrP1-36 as well.
PTHrP1-36 is generated from a full-length form of PTHrP of up to 173 amino acids.
We focused exclusively on peptides generated from PTHrP 1-36, however, products
generated from the remaining 37-173 sequence of PTHrP can impact bone remodeling
[128, 250]. For example, osteostatin is generated via cleavage of PTHrP at amino acids
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107-111/139 and is a potent inhibitor of osteoclastogenesis [187, 251]. The proteases
responsible for generating this fragment have not been identified, but it is tempting to
speculate that MMP generation of osteogenic PTHrP 1-17 coupled with the generation of
osteostatin would further promote the anabolic effects of PTHrP following the resorptive
phase. It is also noteworthy that PTHrP87-107 contains a nuclear localization sequence
that supports osteoblast survival and matrix mineralization [252]. Whether this fragment
is generated by MMPs remains to be explored. Understanding the precise temporal
sequence of how PTHrP is cleaved is needed to define the complex roles it plays in
regulating the catabolic and anabolic phases of bone remodeling.
PTHrP1-36 activation of PTH1R leads to cAMP generation and calcium flux [155].
Our studies show that PTHrP1-17 rapidly induces calcium flux and ERK phosphorylation
in osteoblasts but unlike PTHrP1-36, does not affect cAMP generation or CREB
phosphorylation. Previous studies have shown that ERK phosphorylation is enhanced
via the PKC pathway and promotes osteogenic differentiation [253].

Additionally,

PTH1R-induced cAMP triggers CREB phosphorylation and the induction of RANKL
[229].

In contrast to PTHrP1-36, PTHrP1-17 has no effect on RANKL expression in

osteoblasts. Thus, we posit that PTHrP1-17 activation of PTH1R leads to osteoblast
differentiation and bone formation by promoting calcium flux and ERK phosphorylation.
In accord with this notion, the N-terminal domain of PTHrP and PTH can stimulate
calcium flux via PTH1R [254]. In contrast, other studies have shown that N-terminal
fragments of PTHrP and PTH can stimulate PKA and cAMP activation [155, 160], yet
this effect is not observed in PTHrP1-17-treated primary bone cell cultures and osteoblast
cell lines. In agreement with our findings, a recent study demonstrated that PTHrP 1-16
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does not result in cAMP production but interestingly also had no effect on calcium flux
using PTH1R over expressing CHO-K1 cells [155]. This may indicate that either the
glutamine at amino acid position 17 in PTHrP is an important mediator of calcium flux or
that PTH1R activates different signaling effectors in osteoblasts. Based on PTH1R
knockdown studies it is clear that the effects of PTHrP1-17 are dependent on PTH1R and
not on another GPCR such as endothelin-A [255, 256].
Our discovery of MMP processing of PTHrP has potentially important clinical
implications.

For example, bone metastatic prostate cancer contains both areas of

osteolysis and aberrant bone formation [257]. Osteosarcoma and prostate cancer cells
are now revealed to generate both PTHrP1-36 and PTHrP1-17, which could explain their
divergent effects on osteogenesis rather than osteolysis. This is further supported by
the ability of both PTHrP1-36 [26, 258] and PTHrP1-17 to recruit MSCs and osteoblast
precursors (Figure 2-10). PTHrP1-36 expression is highly associated with osteolytic
lesions such as bone metastatic breast cancer and multiple myeloma. While PTHrP1-17
may also be generated in these skeletal malignancies, the overall balance of osteolytic
to osteogenic factors in these scenarios favors osteolysis. Our current research centers
on the detection of PTHrP1-17 in the serum of prostate cancer patients with primary,
castration resistant, and metastatic castration resistant prostate cancer to determine
whether PTHrP1-17 can be used as a potential readout for occult bone metastases or
progression of bone metastatic disease. We are also using genetic approaches to
eliminate MMPs in the host and cancer cell compartments to identify the key MMP
responsible for the generation of PTHrP1-17 in vivo. Finally, the ratio of PTHrP1-36 to
PTHrP1-17 has implications for other diseases such as osteoporosis, and may potentially
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explain the differential effects of chronic versus intermittent PTHrP administration on
bone resorption versus formation.
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Chapter 3. Prostate Cancer-derived Matrix Metalloproteinase-3
Promotes Tumor Growth in Bone

3.1 Introduction
The matrix metalloproteinases (MMPs) are a family of 17 secreted and 6
membrane bound zinc dependent endopeptidases traditionally associated with the
ability to degrade extracellular matrix (ECM) components [259]. Since the first MMP
was discovered to play a role in tadpole metamorphogenesis in 1962 [260], steady
progress has been made in understanding how these enzymes are secreted and
activated to influence critical biological processes such as embryogenesis and wound
repair. MMPs are also associated with diseases such as cancer, where, based on their
ability to degrade the extracellular matrix rich basement membrane, they were initially
linked to promoting invasion and metastasis. However, it has become evident that
MMPs are not simply extracellular matrix “bulldozers” and in fact collaborate with other
proteases to exquisitely regulate normal physiological and cellular processes including
differentiation, proliferation, and death [261].

3.1.1 Matrix Metalloproteinase Family and History
Historically, the MMP family has been classified into 6 groups: collagenases,
gelatinases, stromelysins, matrilysins, and membrane type (MT). These classifications
were primarily based on their original substrate specificities, sequence similarities, or
domain organization patterns (Table 3-1). Structurally, a prototypical MMP consists of
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an 80 amino acid pro-peptide, a 170 amino acid catalytic domain, a linker peptide (hinge
region), and a 200 amino acid hemopexin domain [262].

With the exception of

membrane type MMPs which remain anchored to the plasma membrane, the majority of
MMPs are secreted as inactive zymogens referred to as proMMPs [259, 263]. Latency
is maintained by the “cysteine switch” mechanism [264], where intramolecular
interactions between a zinc molecule in the catalytic domain’s active site and the
conserved pro-peptide domain cysteine switch motif “PRCGXPD” inhibit proteolytic
activity. Activation is achieved by delocalization of the pro-domain from the catalytic
site. This can occur either by proteolytic cleavage of the pro-domain or by allosteric
activation where the pro-domain is displaced without cleavage [265, 266].

The

conformational change leads to dissociation of the cysteine from the zinc molecule and
replaces it with water [264]. Proteases such as plasmin have been implicated in the
activation of numerous proMMPs, including proMMP-1, proMMP-3, proMMP-7,
proMMP-9, proMMP-10, and pro-MMP-13 [267]. Active MMPs can also to contribute to
the processing and activation of additional proMMPs [268].

Figure 3-1. MMP Structural Domains
The majority of MMPs, including MMP-3, are comprised of a Signal Peptide (SP), Pro-Peptide, Catalytic
Domain, Hinge Region, and Hemopexin Domain. Interactions between the catalytic and pro-peptide
domains maintain proMMPs in their latent zymogen state.
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The catalytic domain has traditionally been regarded as the functional portion of
the enzyme since it is the domain responsible for substrate cleavage. Additionally, the
catalytic domain contributes to substrate specificity via its active site cleft depth and sub
site pockets, along with secondary substrate binding exosites [269]. When a substrate
is bound in the catalytic domain, a water molecule is displaced from the catalytic zinc
ion, leading to protonation of a glutamate residue at the active site and nucleophilic
attack of the carbonyl group of the peptide bond and cleavage of the substrate [262]. A
linker region connects the catalytic domain with the hemopexin domain.

The

hemopexin domain is important for the proteolytic activities of MMPs and is required for
collagenases to cleave the collagen triple helix [270]. It can also contribute to substrate
specificity [271]. Furthermore, several novel non-catalytic functions have also recently
been ascribed to the hemopexin domains of MMP-3, MMP-7, and MMP-9 [272-274].
MMP activity is regulated by the endogenous expression of specific
metalloproteinase inhibitors called tissue inhibitors of metalloproteinases (TIMPs) [268,
275]. TIMPs bind and insert into the MMP catalytic domain of at a 1:1 stoichiometry
[270]. Four TIMPs (TIMP-1, TIMP-2, TIMP-3, and TIMP-4) have been identified, and
there is some evidence suggesting that modulating their expression could be used to
therapeutically target MMPs, however obtaining selectivity would likely prove difficult
due to broad spectrum activity [268].

Additionally, TIMPs possess their own

complicated biological activities independent of MMP inhibition. For example, TIMP-1
and TIMP-2 have both been associated with mitogenic activities of certain cell types,
whereas TIMP-3 has been shown to be pro-apoptotic in certain tumor cells [276].
Therefore, the therapeutic use of TIMPs would need to be approached cautiously.
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Table 3-1. The Matrix Metalloproteinase Family and Groups

Group

MMP
MMP-1

Collagenases

Stromelysins

MMP-8

Enzyme Name
Collagenase-1/Interstitial
collagenase
Collagenase-2/Neutrophil
collagenase

MW kDa

MW kDA

(latent)

(active)

55

45

75

58

MMP-13

Collagenase-3

65

55

MMP-3

Stromelysin-1

57

45

MMP-10

Stromelysin-2

57

44

MMP-11

Stromelysin-3

51

44

MMP-2

Gelatinase-A

72

66

MMP-9

Gelatinase-B

92

86

MMP-7

Matrilysin-1/Pump-1

28

19

MMP-26

Matrilysin-2

28

18

MMP-14

MT1-MMP

63

n/a

MMP-15

MT2-MMP

72

n/a

MMP-16

MT3-MMP

64

n/a

MMP-17

MT4-MMP

70

n/a

MMP-24

MT5-MMP

60

n/a

MMP-25

MT6-MMP/Leukolysin

62

n/a

MMP-12

Macrophage elastase

54

45, 22

MMP-19

n/a

57

45

MMP-20

Enamelysin

54

22

MMP-23

CA-MMP

Unknown
(44?)

Unknown
(34?)

MMP-28

Epilysin

60

50

Gelatinases

Matrilysins

Membrane Type

Others
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3.1.2 MMP Inhibitors and Clinical Trials
Because of their association with diseases like rheumatoid arthritis and cancer,
where high expression often correlates with poor patient prognosis, MMPs were
identified as candidates for pharmacological inhibition [261].

This led to the

development of multiple broad spectrum MMP inhibitors. The first generation of MMP
inhibitors were peptidomimetic, designed by mimicking the protein structure of collagen
at the active site, and incorporated hydroxamate zinc binding groups [123]. However,
alternative zinc binding groups such as carboxylates, hydrocarboxylates, and
sulfhydryls, which coordinated rather than chelated the zinc, were eventually substituted
for hydroxamate to provide greater flexibility and reversibility of the inhibitors. Despite
efficacious anti-cancer activities in several pre-clinical in vivo models, the majority of
these inhibitors failed to meet their endpoints in clinical trials [277, 278]. Reasons for
the unsuccessful outcome are multifold, ranging from an inability to obtain an accurate
readout for activity and efficacy to the actual clinical trial design and patient selection
criteria [123, 277].

These difficulties were further complicated by an incomplete

understanding of MMP biology as well as the design of the predominantly broad
spectrum nature of the inhibitors themselves [277]. Following the unsuccessful clinical
trials, a new approach was taken to study MMPs individually in order to improve
targeting strategies. This new approach led to the generation of non-peptidomimetic
inhibitors that took advantage of a priori knowledge of specific MMP active site 3D
conformations and improved specificity [123]. Subsequent progress has been made
applying a mechanism based targeting approach, leading to modern inhibitors like SC3BT, which has been shown to reduce liver metastasis and improve survival in
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preclinical mouse studies of T-cell lymphoma via selective inhibition of MMP-2 and
MMP-9 [279].

Additional strategies including tetracycline derivatives and natural

products have led to the development of inhibitors like Periostat® (FDA approved for
prevention of periodontitis) and Neovastat (dual MMP/VEGF inhibitor). Together, the
recent progress in developing selective inhibitors by taking advantage of improved
knowledge of MMP biology and advances in chemistry provides rationale for continued
efforts toward MMP inhibition in cancer [123].
3.1.3 Rationale to Study Specific MMPs Individually
An important conclusion from the early MMP inhibitor studies and clinical trials
was that MMP biology is not as distinct as initially thought. Many of the unexpected
side effects observed with the first generation of MMP inhibitors could be attributed to
their broad spectrum nature. For example, batimastat (BB-94) inhibited MMP-1, -2, -3, 7, and -9 [280]. It is now recognized that many MMPs possess protective activities in
addition to their causal roles during cancer progression [281]. Furthermore, despite
their originally described role in extracellular matrix degradation, MMP substrates are
much more diverse than initially known and include many non-matrix substrates such as
growth factors, cytokines, and hormones [261]. Today, the non-matrix MMP substrate
repertoire now significantly out numbers the matrix protein substrate repertoire [282].
There are currently more than 600 identified MMP substrates, and cleavage of
these substrates is often essential for normal physiology [283].

Although the

mechanisms are not fully understood, it is clear that numerous factors including their
catalytic activities, non-catalytic functions, and temporal/spatial expression can
contribute to the mixed roles observed for MMPs during tumorigenesis [284].
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Consequently, MMPs need to be studied individually and with respect to specific tissues
and/or cancers to develop selective inhibitors that will successfully treat disease.
Researchers have looked at the roles of individual MMPs in various cancers such as
breast and skin tumors where both pro- and anti-tumorigenic roles have been observed.
As an example, MMP-7 has been shown to contribute to mammary tumorigenesis [57].
In contrast, ablation of MMP-8 resulted increased incidence of skin tumors in mice,
suggesting that it offers protective roles [285]. Though studies of MMP-3 in cancer have
been limited, the current knowledge of MMP-3 serves as a textbook example of the
evolving field of MMP biology.
3.1.4 Matrix Metalloproteinase-3
3.1.4.1 Discovery, Structure, and Mutants
MMP-3 was first identified in 1985 as a 51,000 kDa proteinase purified from
rabbit synovial fibroblasts treated with tumor promoting agents such as 12-OTetradecanoylphorbol-13-acetate (TPA), cytochalasin B, and poly-HEMA [286].

In

parallel, another group detected a highly expressed cDNA from transformed rat
fibroblasts that went on to also be confirmed as MMP-3 [287]. Additional supporting
evidence linking MMP-3 with cancer was demonstrated using the classic two stage
initiation-promotion model of carcinogenesis, where a single dose of 7,12-DMBA
followed up with repeated applications of TPA leads to the development of squamous
cell carcinomas. Under these conditions, expression of MMP-3 was detected using in
situ hybridization in 5 out of 6 tumors but not in benign papillomas [288]. Subsequent to
these initial findings, many other studies have shown the correlation between MMP-3
and tumor progression [289, 290].
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The utilization of animal models has greatly improved our understanding of
MMPs in pathological situations as well as normal physiology. Understanding roles for
MMPs in normal biology can help to identify those most suitable for inhibition and
potentially avoid MMPs that might cause undesirable off target effects and toxicities if
inhibited.

Many animal models of systemic MMP ablation develop normally, a

phenomenon believed to be a consequence of enzymatic overlap and functional
redundancy in the MMP family [291]. This is true for MMP-3 knockout mice which
display no overt phenotype, however developmental studies have revealed a few
anomalies including altered neuromuscular junction structures [292] and a lack of
secondary branching during mammary gland development [293]. Interestingly, despite
cleaving numerous substrates involved with vascular development, including VEGF
[294], there are no known developmental vascular phenotypes [295]. Also interesting is
the lack of any skeletal abnormalities observed in other MMP null models, including
MMP-9, MMP-13, and MMP-14 [296].
However, as with other MMP knockout animal models, phenotypes in MMP-3
knockout mice can manifest subsequent to challenges such as wound healing and
acute injury. Several studies have reported on the importance for MMP-3 during wound
healing. In particular, excisional wound healing, a necessary step for wound contraction
and closure, is compromised in MMP-3 knockout mice due to deficient actin purse string
formation [297]. Further studies using additional experimental wound models including
dental pulp injury, contact hypersensitivity reaction, and rabbit corneal epithelial wound
also support roles for MMP-3 in wound healing [298-301].
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3.1.4.2 Matrix Metalloproteinase-3 Substrates: Matrix vs. Non-Matrix
MMP-3 cleaves a host of extracellular matrix proteins, including types II, III, IV,
IX, X, and XI collagens, fibronectin, proteoglycans, and laminin [302-304]. Cleavage of
these substrates contributes to the degradation of the basement membrane which
facilitates the long-standing association of MMPs with cancer invasion and metastasis
[296]. Degradation of the extracellular matrix has also been reported to release growth
factors.

Processing of many of these growth factors by MMP-3 can lead to their

activation, inactivation, and occasionally result in novel functions of the cleavage
products (Table 3-2). For example, insulin growth factor binding protein 3 (IGFBP3),
which binds to insulin growth factor (IGF) 1 and 2 to extend its half-life and limit its
activity in circulation was shown to be processed by MMP-3.

The result of this

processing is the release of active IGF-1 or IGF-2. The release of IGFs from IGFBP3
could be blocked by the addition of TIMP-1, implying that the mechanism of activation is
MMP specific [305]. Similar to IGFs, TGF-β activity is regulated by interactions with
other proteins. TGF-β is a well-known mediator of cellular activities and is secreted in a
biologically inactive, latent form consisting of a TGF-β1 homodimer, latency associated
protein (LAP), and latent TGF-β binding protein-1 (LTBP1). Multiple methods of TGF-β
activation have been elucidated, including by proteolysis of the LAP.

Such a

mechanism was demonstrated for MMP-3, where rhMMP-3 was capable of cleaving the
LAP to generate active TGF-β1 in vitro, an activity that could be blocked by both an antiMMP-3 antibody and MMP inhibitors [306]. Similarly, heparin-binding EGF-like growth
factor (HB-EGF) is cleaved in the juxtamembrane region by MMP-3, releasing soluble
and bioactive HB-EGF in vitro. However, the regulation of basic fibroblast growth
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Table 3-2. List of MMP-3 Substrates

MMP-3 Substrate

Biological Result

Reference

α1-Antichymotripsin

Inactivation

[307]

α1-Protease inhibitor

Inactivation

[307]

α2-Antiplasmin

Inactivation

[308]

α2-Macroglobulin

Hydrolysis

[309]

Aggrecan

Degradation

[310, 311]

Antithrombin-III

Inactivation

[307]

Collagens II, III, IV, IX, X, XI

Matrix degradation, growth factor release

[303, 304]

Decorin

Degradation releases TGF-β1

[312]

E-cadherin

Generates soluble ectodomain fragments that promote
EMT and invasion

[313, 314]

Fibrinogen

Degradation

[315, 316]

Fibronectin

Matrix degradation, inflammation/arthritis

[317]

Heparin-binding EGF growth
factor (HB-EGF)

Release of soluble, bioactive EGF

[318]

IGFBP-3

Degradation releases active IGF

[305, 319]

IL-1β

Activation

[320]

Latent TGF-β

Activation

[306]

MCP-1, -2, -3, and -4

Reduction of MCP agonism

[321]

Nidogen

Degradation

[322]

Osteopontin

Enhanced activity (cell migration)

[323]

Ovostatin

Hydrolysis

[309]

Perlecan

Degradation of perlecan releases bFGF

[324]

Plasminogen

Generation of angiostatin-like fragment

[325]

Plasminogen activator
inhibitor-1 (PAI-1)

Inactivation

[326]

Pro-MMP-1, -3, -8, -9, and -13

Activation of the inactive zymogens

[327-330]

Pro-TNFα

Generates active TNFα

[331]

RANKL

Generates soluble RANKL

[211]

SDF-1

Inactivation

[332]

Serum amyloid A

Degradation

[333]

Substance P

Hydrolysis

[334]

Urokinase plasminogen
activator (uPA)

Removes receptor binding domain

[335]
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factor (bFGF) by MMP-3 occurs via a mechanism dependent on its ability to degrade
the extracellular matrix component perlecan to which bFGF is bound. In this scenario,
binding of bFGF with the five domain protein core of perlecan can actually facilitate
presentation of the growth factor to cell surface receptors and receptor activation [336,
337]. MMP-3 has been reported to degrade the protein core of perlecan into multiple
fragments, releasing bFGF, and potentially modulating bFGF bioactivity [324].
An important regulatory ability of MMPs is centered on cleavage and release of
membrane bound molecules such as tumor necrosis factor alpha (TNFα) and FasL.
The TNFα precursor is normally found anchored in the cell membrane and is solubilized
by proteolytic cleavage [338]. It was first reported in 1995 that MMP-3 could cleave a
recombinant pro-TNFα fusion protein to generate the mature TNFα, an observation that
was reversed by adding MMP inhibitors [331].

Fas ligand (FasL) is also a member of

the TNF family, and it is also processed by MMP-3. FasL exists in both membrane
bound and soluble forms, with the soluble form reported to induce both pro- and antiapoptotic activities [339, 340]. Interestingly, MMP-3 was shown to cleave membrane
bound FasL at unique sites that generate novel, pro-apoptotic forms of soluble FasL
[341]. The authors of the study speculate that the distinct MMP cleavage sites may
offer an explanation to the inconsistent activities of soluble FasL. A follow-up study
found that inducing MMP-3 expression in MC3T3 osteoblasts leads to enhanced
solubilization of FasL and subsequent osteoclast apoptosis in a co-culture system [342].
The effect was abolished by specifically targeting MMP-3 using siRNA or inhibitors.
Another TNF family member, RANKL, has been demonstrated to be an MMP-3
substrate as well.

Like TNF-α, RANKL is anchored to the cell surface.
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It signals

through its receptor, RANK, in a juxtacrine manner to drive osteoclastogenesis,
however MMP-3, as well as MMP-7, have been shown to cleave full-length RANKL
[211]. N-terminal amino acid sequencing of the major cleavage product determined that
RANKL was cleaved within the stalk region, suggesting that active, soluble RANKL is
released by MMP-3 and MMP-7.
MMP-3 processing can also modify the activities of its substrates, as is observed
with the cleavage of E-cadherin and osteopontin. It was first observed that expressing
auto activating MMP-3 under control of a tetracycline-regulated promoter in normal
mouse mammary epithelial cells resulted in EMT-like characteristics and increased
invasiveness as determined by modified Boyden chamber assay.

Interestingly, the

application of the broad spectrum GM6001 MMP inhibitor abolished this transformation
[313]. Follow up studies demonstrated that MMP-3 could produce soluble E-cadherin
ectodomain fragments.

These fragments were capable of inducing invasion and

inhibiting cellular aggregation, which is in contrast to the canonical E-cadherin roles of
suppressing invasion and aiding in epithelial aggregation. Osteopontin is a secreted
phosphoprotein, which, like TGF-β, has putative roles in cell migration and survival as
well as wound healing and inflammation [343, 344]. MMP-3 cleaves osteopontin at
three distinct sites. The resulting cleavage products show enhanced activity compared
to full length osteopontin, including migration and recruitment of macrophages [323].
Numerous instances have been also been reported where MMP-3 proteolysis
can lead to inactivation of substrates, such as stromal cell-derived factor-1 (SDF-1) and
monocyte chemoattractant protein-1 (MCP-1). SDF-1 is a chemokine normally involved
in the regulation of hematopoietic stem cell (HSC) proliferation and survival, and it is
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particularly important for the migration and homing of HSCs to the bone marrow [46,
345]. By cleaving the first four residues of SDF-1, MMP-3 processing abolishes the
ability of SDF-1 to bind with CXCR-4 [332]. Similar to the SDF-1/CXCR4 axis, MCP-1 is
a chemokine with normal roles in recruiting and activating monocytes.

Interestingly,

MMP-3 can cleave MCP-1 (as well as other family members MCP-2, 3, and 4),
converting it from an agonist of CC chemokine receptors to an antagonist [321]. The
inactivation of MCPs could play an important part in regulating inflammatory immune
responses.
3.1.4.3 Non-Catalytic Roles for MMP-3
Traditionally, most research has focused on the catalytic domains of MMPs, but
non-catalytic roles for MMPs have recently been described with effects on both cell
migration and survival, adding to the complexity of MMP biology [273, 274]. In addition
to MMP-7 and MMP-9, there is evidence supporting non-catalytic activities for MMP-3
via its hemopexin domain. One study compared the impact of a full length MMP-3
construct with either a construct lacking the hemopexin domain or a construct featuring
a point mutation in the catalytic domain. They found that in addition to inducing
morphological changes characterized by cell scattering and reorganization of F-actin,
the hemopexin domain was required for invasion and branching of mammary organoids
in 3D cell culture gels [346]. The authors went on to discover that these changes were
mediated through the interaction of the hemopexin domain with heat shock protein 90-β
(HSP90β) but noted that additional factors including ANXA2, MARCKS, ADAM10,
ADAMTS15, and Cathepsins A and L may also interact with the MMP-3 hemopexin
domain [346].

In addition, separate reports identified that the MMP-3 hemopexin
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domain alone could stimulate hypermorphic epithelial outgrowth similar to full length
MMP-3 in a mammary fat pad transplantation model [272]. The study showed that the
MMP-3 hemopexin domain interacts with the non-canonical Wnt ligand, Wnt5b, to
sequester and inhibit ligand activity. However, MMP-3 can also proteolytically cleave
the C-terminal domain as an additional mechanism of inhibiting non-canonical Wnt
signaling.

Together, this drives canonical Wnt signaling in the mammary gland as

determined by measuring the levels nuclear β-catenin [272]. The importance of MMP-3
during mammary gland development has been well described, but in light of these new
studies, it is possible that MMP-3 contributes to developmental processes in a noncatalytic manner [293, 313, 347, 348]. Similarly, the combined activities of the catalytic
and hemopexin domains likely contribute to the roles that MMP-3 possesses in different
cancers.

3.1.4.4 Pro- and Anti-Tumorigenic Roles for MMP-3 in Cancer
3.1.4.4.1 Pro-Tumorigenic

MMPs were originally believed to promote cancer progression, and several
examples of MMP-3 promoting tumorigenesis have been reported. A classic example
of this was demonstrated in mammary tumorigenesis, where it was shown that upon
expressing an auto-activating MMP-3 transgene in the SCp2 mouse mammary epithelial
cell line, MMP-3 expression led a more invasive phenotype and enhanced mammary
tumor formation [313]. Similar studies have indicated that inducing MMP-3 expression
in normal mammary epithelial cells caused these cells to produce more invasive,
mesenchymal like tumors [349]. Follow up studies placing MMP-3 under control of the
whey acidic protein (WAP) gene promoter led to the spontaneous development of both
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pre-malignant and malignant lesions in the mammary glands of mice [347]. In these
studies, the effects could be reversed by co-expressing TIMP-1, suggesting that MMP-3
expression was the major factor regulating these changes. Additional studies utilizing
the SCp2 mouse mammary epithelial cells have revealed that MMP-3 treatment induces
a unique splice isoform of Rac1 called Rac1b. Expression of Rac1b led to increases in
cellular reactive oxygen species (ROS) which in turn upregulated Snail and EMT [348].
This same study also showed that genomic instability was enhanced by MMP-3 and that
it could be inhibited using the broad spectrum GM6001 MMP inhibitor. Later work
expanded on these observations and demonstrated that expression of MMP-3 in
mammary epithelial cells stimulated tumor formation and EMT in addition to the
development of fibrosis [350]. More recently, it was shown that the induction of MMP-3
and SNAIL by TGF-β via eIF4E phosphorylation led to the initiation of EMT in primary
mammary tumor cells.

Blocking phosphorylation of eIF4E in a mouse mammary

tumorigenesis model reduced lung metastases [351]. Silencing MMP-3 in 4T1 cells has
also been shown to reduce tumor growth in multiple in vivo mammary tumorigenesis
models and reduce lung metastasis in an orthotopic model [352].
MMP-3 also has contributory roles in other cancers of epithelial origin, including
lung. In a study of primary lung cancer, MMP-3 was shown to induce Rac1b, leading to
EMT and tumor development in vivo [353]. Recently, a similar trend has also been
observed in glioma, where overexpression of Bmi-1, a regulator of tumor suppressor
pathways found upregulated in multiple cancers, led to increased NF-κB activity and
MMP-3 expression in T98G glioma cells. The authors report that these cells acquired
increased metastatic potential as a result [354].
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The cleavage of growth factors by MMP-3 may contribute to some of these
reported pro-tumorigenic roles. For example, MMP-3 proteolysis of IGFBP3 increases
the bioavailability of IGF, a growth factor associated with promoting cancer by
enhancing growth and migration [355, 356]. Studies have shown that MMP-3 cleavage
of IGFBP3 led to enhanced phosphorylation of IGF receptors and increased cellular
proliferation which might promote tumor growth [357]. Similarly, increased availability of
MMP-3 activated HB-EGF or TGF-β might stimulate oncogenesis. It has been shown
that MMP-2 promotes breast tumor survival by controlling TGF-β activity, and MMP-7
can contribute to cutaneous squamous cell carcinoma and colon cancer by releasing
and activating HB-EGF [58, 358, 359]. Another MMP-3 substrate, TNFα, is detected at
higher levels in cancer patients and shown to promote tumor progression by activating
NFkB and AP1 transcription factors (reviewed by [360]). TNFα has been shown to
increase expression of CXCR4 and SDF-1 in ovarian cancer cells lines as well as
patient biopsies leading to increased cell migration [361].

In this manner, MMP-3

mediated solubilization of TNF-α may contribute during tumorigenesis. It has also been
shown that MMP-3 can cleave RANKL, and solubilization of RANKL by MMP-7
increases bone destruction induced by bone metastatic mammary tumors [211, 362].
Whereas many of the MMP-3 mediated proteolytic events are speculated to
contribute to tumorigenesis, the cleavage of osteopontin and E-cadherin by MMP-3
have already been studied and linked to mechanisms that result in pro-tumor effects.
There is a notable association between increased MMP expression and osteopontin
expression during tumorigenesis [363].

In addition to increasing recruitment and

migration of macrophages, MMP-3 generated osteopontin cleavage products also
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enhanced tumor cell adhesion and migration [323]. E-cadherin cleavage also induced
invasive behavior in mammary epithelial cells [314]. Though one could speculate that
this was due to inactivation of E-cadherin, it was determined that the soluble fragments
were actually inducing invasiveness via their own specific activities such as stimulation
of signal transduction pathways [314].
3.1.4.4.2 Anti-Tumorigenic

Multiple instances of anti-tumorigenic roles for MMP-3 have also been reported.
For example, a study in squamous cell carcinoma showed that although MMP-3 is
expressed in all stages of tumor progression, stromal ablation of MMP-3 actually
enhanced tumor initiation, leading to increases in the percentage of mice with surface
lung metastases suggesting that stromal expression of MMP-3 may have a protective
effect [364]. However, tumor-derived MMP-3 might have protective roles as well since a
study in mammary tumorigenesis showed that induced expression of MMP-3 by MMTV
did not yield any spontaneous mammary tumors after 2.5 years. When tumors were
initiated experimentally using DMBA carcinogen, only 32% of the MMP-3 expressing
mice developed tumors compared to 65% of the controls [365]. MMP-3 has also been
shown to reduce invasion of MDA-MB-231 cells through a simulated basement
membrane by degrading plasminogen into fragments that limit laminin degradation
[366].

Interestingly, MMP-3 expression has been shown to be lost in advanced,

aggressive breast cancer, suggesting that these protective roles may manifest clinically
as well [367].

Although there are fewer studies reporting protective roles, they do

suggest that continued studied is needed to fully understand in which cancers, at what
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stages, from which tissues, and by what mechanisms MMP-3 might protects from or
promotes tumorigenesis.
The cleavage of non-extracellular matrix factors by MMP-3 could again explain
some of the anti-tumorigenic roles.

For example, MMP-3 processing abolishes the

ability of SDF-1 to bind with CXCR-4 [332].

Based on the previous studies

demonstrating the importance of this mechanism in facilitating homing to the bone, this
mechanism might offer protection against bone metastasis [47]. MCP-1 has a similar
role to SDF-1. It normally functions to recruit monocytes, but it has been shown to be
hijacked by tumor cells. Stromal MCP-1 has been shown to contribute to breast cancer
and is also expressed by many prostate cancer cell lines and tissue specimens where it
has been implicated in increasing proliferation, migration, and invasion [49, 368]. There
is also evidence that it may be important for angiogenesis [369]. Therefore, inactivation
of MCP-1 by MMP-3 proteolysis may also serve as a protective mechanism during
cancer progression. Interestingly, the effects of TNFα on tumorigenesis can be varied
[360]. While it is often found to correlate with increased tumorigenesis, evidence also
suggests that high doses can lead to haemorrhagic necrosis [370].

High TNFα

expression levels can also synergize with some forms of chemotherapy, likely by
increasing the permeability of tumor vessels (reviewed by [371]). So although MMP-3
solubilization of TNFα could contribute to tumorigenesis as previously discussed, there
is potential for this mechanism to generate anti-tumor effects depending on the context.
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Carcinoma
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MMP-3 expression in normal prostate tissue versus prostate cancer was examined in three previously published datasets via
Oncomine (https://www.oncomine.org). Datasets are publically available and archived as follows: LaTulippe = NCBI GEO
DataSets GSE 68882, Liu = Array Express E-TABM-26, Welsh =
http://public.gnf.org/cancer/prostate/). Asterisk denotes statistical significance (p<0.05).

Figure 3-2. MMP-3 Expression in Normal versus Prostate Carcinoma

3.1.4.5 MMP-3 in Prostate Cancer
In general, MMP-3 has not been studied extensively in prostate cancer. Our own
data-mining

analysis

of

existing

cancer

databases

via

ONCOMINE

(https://www.oncomine.org) shows significantly increased MMP-3 expression in prostate
carcinoma compared to normal prostate tissue in three separate datasets (LaTulippe:
p=0.007, Liu: p=0.001, Welsh: p=0.021) (Figure 3-2) [372-374]. Additional analyses
and wet lab studies of prostate cancer have discovered a mechanism where Eotaxin-1
drives increased MMP-3 expression to promote DU145 prostate cancer cell invasion
and migration [375].

It was also shown that ERα expression in cancer associated

fibroblasts (CAFs) leads to increased thrombospondin-2 (TSP-2) levels and decreased
MMP-3 expression [376]. Co-implantation of 22RV1 prostate epithelial cells with these
CAFs resulted in reduced levels of MMP-3 accompanied by fewer metastases and
reduced angiogenesis in vivo.

In bone, we and others have demonstrated that

numerous MMPs are highly expressed in the tumor-bone microenvironment (Table 3-3),
and several of these MMPs, including MMP-2, -7, and -9, have been shown to regulate
factors that can affect prostate tumor growth [57-59, 211, 362]. However, no studies to
date have looked at the direct impact of MMP-3 on prostate cancer growth in bone, a
common organ for prostate cancer metastasis.

Therefore, we sought to determine

whether MMP-3 might contribute to or protect against tumor growth in bone.
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Table 3-3. Elevated MMP Expression at the Tumor-Bone Interface
Laser capture microdissection and microarray analysis were used to investigate the expression of MMPs
in the tumor-bone microenvironment. Compared to normal bone, MMP expression is increased at the
tumor/bone interface [211].

MMP

Increase at Tumor/Bone
Interface

MMP-13

3403%

MMP-7

1311%

MMP-3

366%

MMP-9

326%

MMP-2

320%

MMP-15

179%

MMP-10

129%

MMP-19

107%

MMP-11

106%

MMP-28

97%

MMP-8

96%

MMP-12

95%

MMP-24

92%

MMP-17

88%

MMP-23

85%

MMP-14

82%

Here we present evidence demonstrating that tumor derived MMP-3 contributes
to prostate cancer growth in bone.

We show that shRNA silencing of MMP-3

expression in prostate cancer cells reduces in vitro proliferation and in vivo intratibial
tumor growth. In analyzing the conditioned media from these cells, we observed higher
levels of the insulin growth factor binding protein-3 (IGFBP3), an established substrate
of MMP-3 and mediator of IGF bioavailability [305, 319]. Further, MMP-3 knockdown
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cells have lower levels of phosphorylated IGF-1R, ERK, and AKT compared to controls,
suggesting that reduced IGF/IGF-1R signaling potentially contributes to the decreased
proliferation. Taken together, our results suggest that tumor-derived MMP-3 contributes
to the growth of bone metastatic prostate cancer.

3.2 Materials and Methods
3.2.1 Tissues, Cell Lines, and Culture
Human prostate to bone specimens were generously provided by Dr. Colm
Morrissey at University of Washington Department of Urology under an Institutional
Review Board (IRB) approved warm body rapid autopsy program. PAIII cells [217],
LNCaP (ATCC), C4-2B (ATCC), PC-3M-luc-C6 (Caliper Life Sciences), and PC3-2M
cells (Perkin Elmer) were grown in either Roswell Park Memorial Institute (RPMI) 1640
medium (LNCaP) or complete Dulbecco’s Modified Eagle’s Medium (DMEM)
supplemented with 10% fetal bovine serum. All cell lines were periodically tested for
mycoplasma (#CUL001B, R&D Systems) and short tandem repeat (STR) verified at the
Moffitt Clinical Translational Research Core. For MMP-3 shRNA knockdown (Origene,
pRFP-CB-shLENTI, #TR30032), PaIII cells were stably transfected and selected using
standard protocols (Qiagen, Superfect, 301305).
3.2.2 Gene Expression Analysis
MMP-3 expression in human prostate cancer was compared to normal prostate tissue
using Oncomine (https://www.oncomine.org). Three publically available prostate cancer
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datasets were examined (LaTulippe, NCBI GEO Datasets GSE 688882; Liu, Array
Express E-TABM-26; and Welsh, http://public.gnf.org/cancer/prostate/).
RNA was extracted with TRIzol® according to manufacturer’s instructions
(Invitrogen #15596). cDNA reverse transcription was performed using a High Capacity
cDNA Reverse Transcription Kit (Applied Biosystems, #4368813). The concentrations of
cDNA samples were determined by Nanodrop, and equal amounts (100ng per reaction)
used for reactions. Primers sequences for genes of interest are: Rat MMP-3 Forward
5’-GATGGTATTCAATCCCTCTATGG-3’;

Rat
Human

AACAAGACTTCTCCCCGCAG-3.’
AGGCAAGACAGCAAGGCATA-3’;

Human

GGTTCATGCTGGTGTCCTCA-3.’

Rat

CGGTTGCTGGGTGTAGTATC-3’;

Rat

GCTCGGAGGAATCAGGACTA-3.’

Human

AATGAAGTCTGGCTCCGGA-3’;

Human

Reverse

MMP-3

Forward

MMP-3
MMP-3
IGF-1R

IGF-1R
IGF-1R

5’-

Reverse

5’-

Forward

5’-

Reverse

IGF-1R

5’-

5’-

Forward

5’-

Reverse

5’-

CCCGCAGATTTCTCCACTC-3.’ 18S Forward 5’-GTAACCCGTTGAACCCCATT-3’;
18S

Reverse

5’-CCATCCAATCGGTAGTAGCG-3.’

GAPDH

Forward

5’-

CCTGCACCACCAACTGCTTA-3’; GAPDH Reverse 5’- CCACGATGCCAAAGTTGTCA3.’

3.2.3 Immunoblotting and Immunostaining
Cells were lysed with cold RIPA (150 mM NaCl, 1 mM EDTA, 1% Triton X-100,
1% sodium deoxycholate, 0.1% SDS, 20 mM Tris pH 8) containing protease and
phosphatase inhibitor (Thermo Scientific, #78442) using standard procedures. Total
protein concentration was determined using BCA (Pierce, #23225) and 25 µg of protein
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loaded in 10% SDS-PAGE gels. Blots were blocked in 5% BSA for 1 hour followed by
primary antibody for phospho-ERK (Cell Signaling Technology #9101; diluted 1:1000 in
blocking solution + 0.1% Tween-20), ERK (Cell Signaling Technology #4695; diluted
1:1000 in blocking solution + 0.1% Tween-20), phospho-AKT (Cell Signaling
Technology #4056, diluted 1:1000 in blocking solution + 0.1% Tween-20), AKT (Cell
Signaling Technology #4691, diluted 1:1000 in blocking solution + 0.1% Tween-20), or
IGF1 Receptor (phospho Y1161) (Abcam #39398, diluted 1:100 in blocking solution +
0.1% Tween-20). The blots were washed 3 x 10min in 1X TBST and incubated with
HRP-conjugated

anti-species

secondary

(Cell

Signaling

Technology,

Rabbit

#7074/Mouse #7076, diluted 1:1000 in blocking solution). Blots were developed using
enhanced chemiluminescence (Pierce 32106) and exposed to light-sensitive film.
Mouse cytokine arrays (Raybiotech, AAM-CYT-3) were performed using conditioned
media obtained by serum starving cells for 16 hours.
For MMP-3 and phospho-Histone H3 immunofluorescence, slides were
deparaffinized and rehydrated to water.

Antigen retrieval was performed using

Proteinase K for MMP-3 and heat-induced (pressure cooker) for phospho-Histone H3.
Slides were blocked with 10% normal serum for 1 hour at room temperature. Primary
antibodies (RH-MMP-3, Triple Point Biologics, 1:100; Pan-Cytokeratin, Sigma Aldrich
C2562.2ML, 1:500; Phospho-Histone H3 (Ser10), Cell Signaling #9701, 1:200) were
incubated overnight at 4C. Slides were washed 3 x 10 minutes in TBST and rinsed in
TBS. Secondary antibodies (Donkey Anti-Mouse Alexa Fluor 488, Thermo Scientific,
1:1000; Donkey Anti-Rabbit Alexa Fluor 568, Thermo Scientific, 1:1000) were incubated
for 1 hour at room temperature.

Slides were washed 3 times and mounted using
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Vectashield anti-fade mounting medium with DAPI (Vector Laboratories, H-1200).
Images were acquired using an upright Zeiss fluorescent microscope.
3.2.4 Growth Assays
Cell proliferation was measured using a Cell Titer 96® Aqueous Non-Radioactive
Cell Proliferation Assay (Promega, G5421). Cells were plated in 96-well plates, 2000
cells per well, and luminescence was measured at 24, 48, and 72 hours on a Victor
plate reader.
3.2.5 In Vivo Tumor Studies
All animal experiments were performed with Institutional Animal Care and Use
Committee (IACUC, #IS000001283, CCL) approval from the University of South Florida.
To test the effect of MMP-3 on in vivo tumor growth in bone, 5 x 104 PaIII cells (10 µL of
ice cold PBS) were intratibially innoculated into immunocompromised male Rag2-/- mice
(10 mice per group). A sham injection (10 µL) of PBS was injected in the contralateral
limb to control for bone injury. Bioluminescent imaging (120 mg/kg luciferin in sterile
PBS, Gold Biotechnology, LUCK-1G) was performed 24 hours after surgery and every
48 hours after as a correlate of tumor growth (IVISTM Perkin Elmer). After 10 days,
study animals were sacrificed and tumor and sham bearing limbs (tibia) were collected
and fixed overnight in 10% neutral buffered formalin and transferred to 70% ethanol for
ex vivo x-ray (Faxitron X-ray Corp) and µCT (Siemens). Following ex vivo analysis,
bones were decalcified for 3 weeks in 14% EDTA (changed twice weekly) and
processed for paraffin embedding. Subsequent to processing and embedding, trichrome
staining was used to identify areas of trabecular bone formation (blue/green staining of
type I collagen). Bone area to total area (B.Ar./T.Ar.) was determined by measuring
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trabecular bone volume within a 1.0 mm long area beginning 0.5 mm distal from the
growth plate using ImageJ software [219].

3.3 Results
3.3.1 MMP-3 is Expressed in Bone Metastatic Prostate Cancer Patient
Specimens.
To test whether MMP-3 is expressed by human bone metastatic prostate cancers
and determine the clinical relevance of its expression, we co-immunostained for
cytokeratin, a marker of epithelial cell types, and MMP-3 in prostate to bone metastases
derived from patients enrolled in the rapid warm body autopsy program at the University
of Washington. We observed positive co-staining for MMP-3 and cytokeratin in 8 of the
9 examined patient specimens (Figure 3-3). We also noted MMP-3 positive staining in
bone lining and stromal cells. Interestingly, the single specimen that did not co-stain for
MMP-3 and cytokeratin did show positive staining for MMP-3 in the stroma. These
results are consistent with previous reports, showing that MMP-3 is expressed by
prostate cancer cells and stromal cells.
3.3.2 MMP-3 is Expressed in Prostate Cancer Cell Lines
To select a model for subsequent in vitro and in vivo studies, we assessed
whether MMP-3 was expressed in prostate cancer cell lines (LNCaP, C4-2B, PC3-M,
and PaIII) according to their ability to establish tumors in bone in vivo. Our data show
that MMP-3 is expressed by each of these cell lines (Figure 3-4 A). We selected PaIII
for further study because of its strong expression of MMP-3 and its ability to recapitulate
mixed osteoblastic and osteolytic lesions in intratibial mouse models [377, 378]. Using
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RFP tagged MMP-3 shRNA constructs we generated two stable MMP-3 knockdown
PaIII clones and an shRNA control cell line (Figure 3-4 B-C).

Figure 3-3. MMP-3 is Expressed by Tumor Cells in Human Prostate to Bone Metastases
Expression of MMP-3 in human prostate to bone metastasis patient sections (n=9) was determined by
staining with anti-cytokeratin (green) and anti-MMP-3 (red) antibodies via fluorescent microscopy.
Representative images for 3 of 9 patients are shown. Scale bars are 100 µm. Dashed box denotes area
of magnification.
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Figure 3-4. MMP-3 is Expressed in Multiple Prostate Cancer Cell Lines
(A) MMP-3 expression in LNCaP, C4-2B, PC3-M, and PaIII prostate cancer cell lines. –ve indicates
negative non-template control. Molecular weight markers are illustrated in base pairs (bp). (B and C)
PaIII cells were stably transfected with MMP-3 and control red fluorescent protein (RFP) labeled shRNA
construct to achieve MMP-3 silencing. Scale bars are 100 µm.

3.3.3 MMP-3 Silencing Decreases PaIII Prostate Cancer Cell Growth In Vitro
Previous studies have demonstrated that MMP-3 can proteolytically regulate a
variety of factors involved in cell growth. Therefore, we assessed the impact of MMP-3
silencing on in vitro cell growth using bioluminescence as a readout for proliferation.
MMP-3 silencing decreased proliferation of PaIII prostate cancer cells as early as 24
hours, and these effects became more pronounced at later time points (Figure 3-5).
Our stable cell lines express two different levels of MMP-3 (Figure 3-4 B), and the
reduction in proliferation corresponded with MMP-3 expression levels in these cell lines.
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Figure 3-5. MMP-3 Promotes PaIII Proliferation
PaIII shControl, shMMP-3 polyclonal, shMMP-3 Clone 01, and shMMP-3 Clone 02 were seeded in 96 well
3
plates (2 x 10 cells/well) and luminescence measured at 24, 48, and 72 hours as a surrogate for cell
proliferation. Asterisk denotes statistical significance (p<0.05); n.s. = non-significant differences.

3.3.4 Prostate Cancer Growth in Bone is Reduced by MMP-3 Silencing
To study the effect of MMP-3 expression on prostate tumor growth in bone, we
injected PaIII shControl and PaIII shMMP-3 Clone 01 cells intratibially into male Rag2-/C57BL/6 mice (5 x 104 cells, 10 mice per group) and monitored tumor growth by
measuring bioluminescence over time (Figure 3-6 A). Tumors in the mice injected with
PaIII shMMP-3 cells grew at a significantly slower rate compared to control tumors
(Figure 3-6 B). After 10 days, mice were sacrificed and we performed ex vivo analyses
of the tibias to study cancer associated bone disease including X-ray, µCT, and bone
histomorphometry. Prostate tumor growth in bone induces extensive remodeling. To
determine if there were any differences between PaIII shControl and PaIII shMMP-3
tumors on induction of osteolysis, X-ray analysis (Faxitron) was performed.
Quantification of osteolytic lesion area (dark spots observed on bone surface) to total
bone area showed that there was no significant difference in tumor-induced osteolysis
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between PaIII shControl or PaIII shMMP-3 (Figure 3-7 A). In addition to osteolysis,
bone metastatic prostate tumors can induce trabecular bone formation. We used µCT
and trichrome staining/image quantification to study if there were any differences
between PaIII shControl and PaIII shMMP-3 tumors on induction of osteogenesis and
observed no significant change in trabecular bone volumes (Figure 3-7 B-C). Together,
these data suggest that MMP-3 contributes to prostate tumor growth in bone but does
not significantly alter the bone microenvironment or structure.

Figure 3-6. MMP-3 Silencing Reduces In Vivo Prostate Tumor Growth in Bone
4

(A) PaIII shControl and shMMP-3 Clone 01 cells (5 x 10 in 10 µL) were injected intratibially in 6 week old
-/male Rag2 mice (n=9/group). Saline was injected in the contralateral limb to control for injury.
Bioluminescence was measured to monitor tumor growth for 10 days. (B) Linear regression analysis of
tumor growth rates over 10 days (PaII shControl = red, PaIII shMMP-3 = blue).
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Figure 3-7. MMP-3 Silencing in PaIII Tumor Cells Does Not Alter Tumor-Induced Changes in Bone
Structure
(A) X-ray analysis and quantitation of tumor-induced osteolysis in tibias bearing PaIII shControl and
shMMP-3 Clone 01 tumors. (B) µCT analysis and quantitiation of trabecular bone volume in tumor
bearing tibias. (C) Trichrome stained sections derived from PaIII shControl and shMMP-3 Clone 01 tumor
bearing tibias were quantitated for the amount of trabecular bone (blue-green color). n.s. = nonsignificance.

3.3.5 Candidate Approach to Assess MMP-3 Mechanism of Action
To gain further insight into the mechanism by which MMP-3 contributes to in vitro
and in vivo cancer cell growth, we performed cytokine array analysis of 62 cytokines to
study the secreted protein content of conditioned media from PaIII shMMP-3 and PaIII
shControl cell lines (Figure 3-8 A). Conditioned media was collected by serum starving
cells overnight and diluting to equal total protein concentrations as determined by BCA.
Densitometry analysis of the array blots revealed that several proteins in the
conditioned media of PaIII shMMP-3 cells were increased over control, including insulin
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growth factor binding proteins (IGFBPs) 3, 5, and 6 (Figure 3-8 B). In contrast, the
internal control was actually slightly decreased as assessed by densitometry analysis
(LI-COR Image Studio), suggesting that these increases in IGFBPs were even greater
(not shown). Notably, IGFBP3, an established MMP-3 substrate, was among the most
elevated (1.59-fold over control). The PaIII conditioned media was collected after only
16 hours of incubation, so we would expect more remarkable increases with longer
incubation periods. These data show that MMP-3 silencing in PaIII cells results in
increased levels of IGFBPs, including IGFBP3, indicating that the MMP-3 processing of
IGFBP3 may be important for the observed growth effect in MMP-3 knockout PaIII cells.

Figure 3-8. IGFBPs are Elevated in MMP-3 Silenced PaIII Cancer Cell Conditioned Media
(A) Cytokine array blots from PaIII shControl and PaIII shMMP-3 cell line conditioned media.
Densitometry analysis of cytokine array blots (Licor Image Studio).
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(B)

Figure 3-9. Insulin Growth Factor Receptor (IGF-1R) Signaling Pathways
IGF-1R is a cell membrane receptor tyrosine kinase (RTK) responsible for mediating insulin-like growth
factor (IGF-1) activity in wide range of tissues and organs. Activation of either the MAPK or PI3K
mediates biological processes like cell proliferation, growth, and survival. The bioavailability of IGF-1 in
circulation is tightly modulated by six IGFBPs such as IGFBP-3.

3.3.6 Reduced IGF-1R Activity in PaIII shMMP-3 Cells
IGFBP3 binds and sequesters IGF proteins (IGF-1 and IGF-2) with high affinity to
modulate their activity, predominantly resulting in anti-proliferative and anti-growth
effects by preventing activation of the insulin growth factor receptor (IGF-1R) (Figure
3-9). To test if MMP-3 effects on proliferation were associated with reduced IGF-1/IGF1R signaling, we first assessed the expression of IGF-1R in the PaIII cell lines by PCR.
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Both the PaIII shControl and PaIII shMMP-3 cell lines showed robust IGF-1R
expression (Figure 3-10 A). We next looked at the phosphorylation of IGF-1R and its
downstream kinases ERK and AKT in PaIII shControl and PaIII shMMP-3 cell lines
grown under standard culture conditions (no stimulation) by Western blot.

These

studies indicated a reduction of IGF-1R phosphorylation in PaIII shMMP-3 cell lines
compared to PaIII shControl when normalized to Actin as a loading control. Reduced
IGF-1R phosphorylation was accompanied by decreases in both ERK and AKT
phosphorylation, both of which are potent inducers of proliferation, when normalized to
total ERK or total AKT loading controls, (Figure 3-10 B-C). The contribution of MMP-3
expression to tumor growth was also observed in tissue sections derived from in vivo
intratibial tumor growth studies by calculating the mitotic index (MI). Using phosphoHistone H3 immunofluorescence staining, an indicator of cells undergoing mitosis, and
Definiens histology analysis software, we calculated the number of cells undergoing
mitosis versus the number of cells not undergoing mitosis and noted a significant
decrease in the MI for PaIII shMMP-3 tumors (PaIII shControl = 20.37% vs. PaIII
shMMP-3 = 4.33%) (Figure 3-10 D). Taken together, these data show that reduced
proliferation caused by MMP-3 knockdown in PaIII prostate cancer cells is potentially a
result of decreased IGF-1R signaling.
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Figure 3-10. MMP-3 Silencing Reduces IGF-1R Signaling
(A) IGF-1R expression in PaIII shControl and PaIII shMMP-3 cells. –ve indicates negative, non-template
control. Molecular weight markers are illustrated in base pairs (bp). (B) IGF-1R phosphorylation in PaIII
shControl, shMMP-3 Clone 01, and shMMP-3 Clone 02 cells. (C) Phosphorylated ERK(pERK), total ERK
(nERK), phosphorylated AKT (pAKT), and total AKT (nAKT) in in PaIII shControl, shMMP-3 Clone 01,
and shMMP-3 Clone 02 cells. +ve indicates positive control (mouse mesenchymal stem cells stimulated
with epidermal growth factor (EGF)). (D) Phospho-Histone H3 immunofluorescence staining and
quantitation in tissue sections derived from PaIII shControl and shMMP-3 Clone 01 tumor bearing tibias.
Percentages of total cells (blue) stained positive for phospho Histone-H3 (red=high, orange=medium,
yellow=low) per 20x field were calculated. Asterisk denotes statistical significance (p<0.05).

3.4 Discussion
MMPs have been shown to be overexpressed in many cancers, where they
possess both pro- and anti-tumorigenic roles by degrading and regulating extracellular
and non-extracellular matrix proteins [280]. Here, we have shown that silencing MMP-3
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in prostate cancer cells inhibits their growth in vitro and in vivo. Further, we found
increased levels of IGFBP3, a known MMP-3 substrate [305], and decreased IGF-1R,
ERK, and AKT phosphorylation in the MMP-3 silenced cells.

This suggests that

increased MMP-3 expression by prostate cancer cells contributes to tumor growth by
cleaving IGFBP3, thereby increasing the activity of the proliferation driving IGF-1/IGF1R signaling pathway. This has important clinical implications for the future treatment of
metastatic prostate cancer as the development of both MMP and IGF-1R inhibitors
progresses.
Previous studies of MMP-3 in cancer have shown pro- and anti-tumorigenic
roles. For example, in breast cancer there are conflicting reports where MMP-3 can
contribute or protect during cancer progression [347, 349, 365, 366]. It is possible that
the net effect of MMP-3 could change as the disease advances, therefore MMP-3 needs
to be studied in a context dependent manner. In prostate cancer, MMP-3 is detected at
higher expression levels compared to normal prostate tissues, however there have only
been a couple of MMP-3 focused studies. These studies have shown that MMP-3
expression contributes to metastasis and angiogenesis [376] and migration and
invasion [375], but no studies to date have looked at the direct impact on prostate
cancer growth in bone.

Our studies found that tumor-derived MMP-3 expression

contributes to prostate cancer cell growth in vitro as well as tumor growth in bone using
in vivo intratibial models. Additionally, we noted that in addition to expression by tumor
cells in our human prostate to bone metastasis samples, MMP-3 is expressed in stromal
cell types. There is evidence that the roles of MMPs can depend on tissue expression,
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therefore it would be interesting to study the specific impact of stromal MMP-3 in bone
metastatic prostate cancer in future studies.
Prostate cancer to bone metastasis induces extensive remodeling of the bone
and is hallmarked by a combination of osteogenesis and osteolysis. Despite its effects
on tumor growth in bone, our studies did not reveal any significant differences in tumorinduced osteolysis or osteogenesis by MMP-3 expression. MMP-3 can cleave many
important factors involved with bone remodeling, including PTHrP, RANKL, and TGF-β,
in addition to its extracellular matrix remodeling capacities, so it is surprising that no
differences were observed. However, previous studies of MMP-3 knockout mice have
revealed no skeletal phenotypes, unlike others such as MMP-2, -9, and -13 which
demonstrate significant skeletal impairments.
Numerous MMP-3 substrates have been previously identified, and these
substrates are often responsible for determining pro- and anti-tumorigenic effects. Like
other MMP studies, we must also consider the spatial and temporal expression of the
proteases.

Our cytokine array identified several proteins expressed by the PaIII

prostate cancer cells, so it is plausible that these might co-localize with MMP-3.
IGFBP3 is a known target of MMP-3 while IGFBP5 and IGFBP6 can be processed by
MMP-2, -7, -9, or -12 [379-381]. However, IGFBP5 and 6 bind with greater affinity to
IGF-2 whereas IGBP3 binds preferentially to IGF-1 [382]. In addition to IGFBP3, 5, and
6, we observed increased VEGF in the conditioned media of PaIII shMMP-3 cells.
Previous studies have shown that matrix bound VEGF-A can be released and
processed into soluble fragments by multiple MMPs, including MMP-3, which
possessed altered neovascular activities compared to an MMP-resistant form of VEGF
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[294]. Further studies have shown that MT1-MMP can increase VEGF-A transcription
by interacting with vascular endothelial growth factor receptor 2 (VEGFR-2) [383], but it
is unclear whether this effect can be induced by other MMPs. We also noted increased
levels of additional proteins such as Eotaxin1 and G-CSF. To our knowledge, these
have not been previously shown to be regulated by MMPs, but might be interesting to
investigate if and how MMP-3 modulates their expression.

It is worth noting that

Eotaxin1 was shown to increase MMP-3 expression in DU145 cells which led increased
invasiveness and migration [375], suggesting a possible reciprocal interaction.
Similarly, there are reports where G-CSF stimulates MMP-2 expression and migration in
mesenchymal stem cells [384].

Although our results implicate reduced IGF/IGF-1R

signaling, it is both plausible and likely that other signaling pathways are affected by
MMP-3 silencing and may contribute to the differences noted in proliferation and tumor
growth.
Given the numerous pro- and anti-tumorigenic roles described for MMP-3 in
other cancers, MMP-3 may not be the best suited for the development of selective
inhibitors. However, uncovering the pro- and anti-tumorigenic roles for MMP-3 and
elucidating its substrates provides alternative therapeutic targets. IGF-1 is expressed
by bone osteoblasts, osteoclasts, and osteocytes where its downstream signaling
events are vital for development and metabolism [385]. The roles of the IGF signaling
axis have also been well documented in many cancers where it is predominantly
associated with pro-growth and pro-survival effects on tumor cells [355]. Studies have
also shown that the IGF axis is involved in development and progression of prostate
cancer [356].

IGF-1 and IGF-2 have both been implicated in the proliferation and
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invasion of prostate cancer cells and progression to androgen independence, however
there is some controversy as studies of transgenic mice have demonstrated that
deletion of IGF-1R in combination with inactivation of p53 in prostate cells could lead to
more aggressive cancer [386]. Both tumor- and bone-derived IGF-1 is also a factor in
the “vicious cycle” [387, 388], suggesting that IGF-1/IGF-1R signal transduction may be
particularly potent in prostate to bone metastases.

Consistent with most

epidemiological findings, our results suggest that reduced IGF-1R signaling in the PaIII
shMMP-3 cells decreases proliferation in vitro and in vivo. Based on the predominantly
oncogenic effects of the IGF-1R pathway, there are numerous ongoing efforts to target
the IGF signaling axis in prostate cancer.

Preclinical studies of both monoclonal

neutralizing antibodies and tyrosine kinase inhibitors have consistently shown
therapeutic efficacy, but their performance in clinical trials have generally been
disappointing or complicated by a wide array of side effects [382]. This is likely a
product of the ubiquitous tissue expression of IGF-1R and its important physiological
functions. One current approach to improve the efficacy of IGF-1R inhibitors in prostate
cancer is to give them in combination with other therapies, including androgen
deprivation and chemotherapy [389]. According to these and previous findings from our
group, we would speculate that developing a dual inhibitor consisting of an IGF-1R
inhibitor and a bone seeking bisphosphonate might improve these therapies. The use
of this strategy has greatly improved the efficacy of MMP inhibitors in bone metastatic
disease by permitting tissue selective (i.e. bone) targeting [123, 124]. We hypothesize
that this strategy would reduce the local activities of IGFs while preserving IGF-1R
signaling in normal, non-cancerous tissues. In conclusion, we have shown that MMP-3
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contributes to prostate cancer growth in bone by increasing tumor cell proliferation, and
that the cleavage of IGFBP3 by MMP-3, which regulates IGF-1 activity, potentially
contributes to the increased proliferation.
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Chapter 4. Summary, Clinical Implications, and Future Work
Metastasis is a chief component of cancer mortality, being responsible for up to
90% of cancer deaths [390]. Cancer can metastasize to multiple organs including the
lungs, brain, lymph nodes, liver, and bone. For reasons that are only beginning to be
understood, certain cancers metastasize more prevalently to specific organs, with the
predilection of prostate cancer cells to colonize bone being a case in point. Today, men
diagnosed with primary, localized prostate cancer have a favorable prognosis with a 5year survival rate of nearly 100% [4]. As evidenced by these statistics, early detection
is the best scenario, but the clinical reality is that a significant number of men will initially
present with advanced prostate cancer and have bone metastases already established.
Given the associated decline in quality of life and high mortality rates for metastatic
cancer, discovering the underlying mechanisms of bone metastasis and developing
clinically translatable therapies is of the utmost importance. Equally important is the
development of improved strategies to screen men for prostate cancer and carefully
identify and monitor patients with early stage disease who are at risk for developing
metastases.
The original vicious cycle of bone metastasis describes the interactions between
tumor cells, osteoblasts, and osteoclasts, but new components and mechanisms are
continually being integrated [56]. By improving our understanding of the disease, these
additions will provide potentially novel therapeutic targets. Although MMPs have been
implicated in invasion and metastasis for nearly 3 decades, work from our lab and
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others has expanded these roles, demonstrating that many MMPs are involved in
regulating vicious cycle cytokines and growth factors such as RANKL, IGF, TGF-β,
VEGF, and now PTHrP [53]. PTHrP has long been acknowledged for its potent bone
resorbing capacities in skeletal malignancies like breast cancer and multiple myeloma,
but it can also promote osteogenesis via its actions on the osteoblast compartment
when dosed intermittently [26, 167]. Our data show that MMP cleavage of mature
PTHrP1-36 generates a 17 amino acid N-terminal peptide (PTHrP1-17) that does not
induce osteoclastogenesis while retaining the ability to induce osteoblast differentiation
and stimulate bone formation. This mechanism could potentially explain why some
cancers, such as prostate, generate predominantly osteogenic lesions. Interestingly, in
our mass spectrometry analysis of cancer cell conditioned media, PTHrP 1-17 was
detected in prostate cancer and osteosarcoma cell conditioned media, both of which are
characterized by osteogenesis and bone forming lesions, but not in breast cancer which
is traditionally hallmarked by the presence osteolytic lesions.

A more extensive

characterization of cell lines and in vivo specimens would be necessary to draw further
conclusions, but it would be fascinating to investigate whether PTHrP 1-17 is found most
often in cancers that produce osteogenic metastases and to better understand the
interplay of factors related to the osteolytic/osteogenic balance.
We have also shown that there is selectivity of MMPs toward PTHrP. As an
example, MMP-13 does not generate PTHrP1-17. Our laser capture microdissection and
microarray analysis of MMP expression was performed on prostate to bone metastases,
showing significantly increased expression of MMP-2, -3, -7, -9, and -13. Although
these MMPs are known to be increased in many cancers, it would be interesting to
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perform a similar experiment on bone metastases from other cancers, such as breast,
to study the differential expression of MMPs. Importantly, the increased commercial
availability of reliable fluorometric MMP activity assays will allow us to explore the actual
activity of MMPs in bone metastatic cancers of different origins. This information might
help us to better understand the MMP mediated generation of PTHrP 1-17 and possibly
yield clues to explain the osteolytic versus osteogenic pathologies observed in bone
metastases.
Currently, prostate specific antigen (PSA) is the standard test for screening men
for prostate cancer. PSA is a serine protease produced by prostate cells that can be
measured in blood. Usually, men with prostate cancer have elevated PSA levels (>4.0
ng/mL), but benign conditions or infections can also cause PSA levels to rise [391].
Because of this, there is controversy surrounding the use of this test, including who
should and should not be tested and what levels constitute cause for concern [391]. A
primary problem with PSA screening is that the tests have been known to report both
false-negatives and false-positives. One study reported that only about 25% of men
with elevated PSA who underwent a prostate biopsy actually had prostate cancer [392].
Although PSA is likely to remain the standard screening method for the foreseeable
future, and efforts are being made to improve its accuracy, there is also pressure to find
new prognostic biomarkers. Recently, it was reported that a PTHrP12-48 fragment could
serve as plasma-derived biomarker associated with bone metastasis in breast cancer
patients [175]. Given the osteogenic nature of both prostate to bone metastases and
MMP generated PTHrP1-17, perhaps PTHrP1-17, or PTHrP fragments that we have yet to
study, might correlate with bone metastasis in prostate cancer. Using the PTHrP1-17
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antibody and mass spectrometry will allow us to study serum, plasma, and urine from
prostate cancer patients with or without bone metastases and determine any
correlation. In addition to prognostic uses, the levels of PTHrP1-17 might also correlate
with the effectiveness of experimental therapies such as MMP inhibitors.
Besides their functional roles, MMPs may hold potential as prognostic or
diagnostic cancer biomarkers as well.

Multiple MMPs from readily available sources

like urine, serum, and plasma have been evaluated in cancers such as colorectal,
pancreatic, breast, ovarian, bladder, prostate, and lung [393]. In some instances, the
expression of certain MMPs has been found to correlate with the presence, stage,
and/or grade of disease.

For example, the study of MMP-9 in breast cancer has

revealed that plasma levels actually decrease following primary tumor resection. In
patients who relapse, increases in plasma levels of MMP-9 are detected. Notably, the
rise in MMP-9 expression is detected prior to the actual clinical diagnosis of recurrence
[394]. Although MMP-3 is not currently used as a biomarker, existing data where its
expression correlates with poor prognosis in colorectal cancer, and serum levels of
MMP-3 in oral squamous provide rationale for its consideration and further study [289,
290].
Within the bone field, there is a need for agents capable of stimulating bone
formation to treat diseases like osteoporosis. The use of PTH and PTHrP has been
studied for these purposes after it was first shown in the 1930s that intermittent/daily
injections of PTH could lead to increases in bone formation [128, 395]. However, the
anabolic effects are only manifest when PTH is administered intermittently. Sustained
exposure favors osteoclast formation by driving the production of RANKL from
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osteoblasts.

Following its discovery, it was determined that PTHrP had anabolic

activities similar to PTH, but PTHrP1-36 was initially thought to be free of PTH’s potent
resorptive effects [148, 149]. In a 3-month trial comparing PTHrP and PTH in three
groups of 35 post-menopausal women, PTHrP1-36 increased bone mineral density, and
although there was a slight delay compared to PTH1-34 (2-mo vs. 3-mo), PTHrP1-36
treatment eventually led to increased CTX bone resorption markers [396]. Differences
in potency were also noted, with the lower potency of PTHrP 1-36 being attributed to its
restriction to the cell surface whereas PTH1-34 was more readily internalized and able to
persistently signal through PTH1R. Additionally, it is believed that the susceptibility of
PTHrP1-36 to proteolytic cleavage might limit its bioavailability and usefulness as a
systemic treatment [128].
Although the native, full-length PTH and PTHrP proteins may not be best suited
as anabolic treatments, there has been strong interest in using the PTH or PTHrP
structure as a starting point to develop peptide analogs that promote bone formation.
Currently, one PTH analog called teriparatide (FORTEO®) is FDA approved for the
treatment of osteoporosis.

Although effective, practitioners have noted that some

patients experience severe hypercalcemia which can actually lead to bone loss [397,
398]. Recently an analog based on PTHrP called abaloparatide was developed as an
alternative to teriparatide and is currently being investigated in phase III clinical trials.
Abaloparatide modifies 5 of the 13 residues between amino acids 22 and 34 of PTHrP,
however the rationale for these changes has not yet been published or explained.
Results of earlier clinical trials show that abaloparatide increases bone mineral density
and reduce fractures in post-menopausal women, however any risk or potential for bone
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resorption has not been mentioned [151]. In our studies, MMP generated PTHrP1-17
retains the anabolic activities of PTHrP1-36 but does not stimulate bone resorption.
During ectopic ossicle formation assays, mice were systemically administered daily
(intermittent) PTHrP1-17, and post-mortem histomorphometry of long bones revealed
increases in trabecular bone volume.

Importantly, using in vivo calvarial injection

assays, a protocol specifically designed to stimulate bone resorption via continuous
exposure to PTHrP, we found that PTHrP1-17 neither increased osteoclast numbers nor
enhanced bone resorption, both of which were observed with PTHrP 1-36. Furthermore,
our in vitro analyses suggest that PTHrP1-17 may not be further degraded proteolytically
as it was still detected after an hour of incubation with MMPs as well as in cell culture
conditioned media collected over 24 hours. Therefore our bioactivity studies of PTHrP 117

suggest that the N-terminal residues are capable of eliciting anabolic effects and may

hold potential for further development as an anabolic agent for treating bone disease.
Our mass spectrometry studies indicate that multiple MMPs can generate
PTHrP1-17, including MMP-2, -3, -7, and -9 but not MMP-13, suggesting that there is
specificity for certain MMPs toward the PTHrP sequence or structure. Although we
have explored the activity of MMP-3 toward PTHrP at multiple timepoints and focused
on MMPs highly expressed in the tumor-bone microenvironment, it would be interesting
to see which other MMPs are capable of cleaving PTHrP and to further study the
kinetics of these enzymes. Since numerous proteases, including several MMPs, are
found in the tumor microenvironment, it will be important to understand these dynamics.
We know that enzymes like PSA and neprilysin can cleave PTHrP [168, 169], but it
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remains to be determined if and how they might compete with MMPs and other
proteases in vivo.
In future studies, we would like to explore whether PTHrP1-17 is produced by
normal tissues where it might possess roles during routine skeletal metabolism.
Osteoblasts are known to produce PTHrP [147], therefore we would evaluate PTHrP1-17
in a panel of osteoblast, osteoblast-like, and osteocyte cell lines. Our lab and others
have developed and maintain colonies of MMP-null mice, including MMP-2, MMP-3,
MMP-7, and MMP-9, that would allow us to study if there is a predominant MMP
involved in PTHrP processing and compare this to WT mice.

Initially, we could

establish primary mesenchymal stem cell and osteoblast cultures from these mice and
examine the secretion of PTHrP1-17 in the conditioned media. We could also collect
plasma and bone marrow flushes from these mice as a more relevant in vivo source for
immunoprecipitation and mass spectrometry analysis. To further our understanding of
PTHrP processing by MMPs in a prostate cancer setting, we could use CRISPR or
traditional RNA interference methods to silence select MMPs in vitro. This could be
done in PaIII cancer cells as we know they secrete detectable levels of PTHrP 1-17 and
can be used for in vivo intratibial models. The development of the PTHrP1-17 specific
antibody and refined mass spectrometry protocols for its detection will be a valuable tool
as we continued to study PTHrP processing in more detail in the future.
In this work, we have primarily focused on PTHrP1-17 as it appears to retain
partial similarity to the mature, full length form of PTHrP. However, our studies found
that several MMPs could generate PTHrP18-26 and PTHrP27-36 as well as fragments from
PTHrP1-36. Although they did not possess activity in our signaling assays, nor did they
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antagonize the activities of PTHrP1-17 or PTHrP1-36, there could be as of yet to be
determined roles for these fragments. We also have not studied the effects of MMPs on
the C-terminal (amino acids 37-141) portion of the protein. Many fragments and protein
products have been detected from this region, including osteostatin, which has multiple
previously identified anti-resorptive activities [181].

Surprisingly, very little is known

about the proteases involved in cleaving this portion of PTHrP. Therefore, in future
work, we would like to investigate if MMPs are involved in the generation of osteostatin
or other novel fragments from the C-terminus.
The interaction between PTHrP1-17 and PTH1R leaves unanswered questions as
well.

Normally, PTHrP interacts with PTH1R by the “two site model,” however the

PTHrP1-17 fragment lacks the C-terminal portion of PTHrP that has been shown to
interact with the receptor’s N-terminal domain. Using available resources at Moffitt, we
could use protein crystallization to develop a model of PTHrP 1-17/PTH1R interaction and
visualize the precise orientation of receptor ligation.

It may also be possible that

PTHrP1-17 and/or other fragments could elicit cellular activities by alternative receptors.
Researchers in the field have speculated that the Endothelin receptor could be involved
with signaling of other PTHrP fragments like PTHrP 1-16, however further study of this
idea is needed [256]. We have explored this idea briefly using affinity precipitation
mass spectrometry where we treat osteoblasts with biotinylated PTHrP1-17 and
immunoprecipitate to observe protein binding partners. We would like to expand these
studies in future work as it could offer valuable directions in determining additional
activities for PTHrP1-17.

In addition to studying PTHrP1-17 in osteoblasts, we would
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include prostate cancer cell lines as well.

Identifying binding partners or receptors

involved in prostate cancer cells could reveal possible reciprocal effects of PTHrP 1-17.
Persistent research has gradually elucidated cancer specific roles for individual
MMPs, and we are beginning to have a clear picture of which MMPs contribute versus
protect during tumorigenesis. For example, MMP-3 has been implicated in contributing
to mammary tumorigenesis but protecting in squamous cell carcinoma [313, 364]. Our
tumor growth studies have focused on MMP-3 produced by the cancer cells. Although
most MMPs are secreted, they can act locally and unique roles for MMPs derived from
specific cell types have been reported [58, 362].

Therefore, it is possible that

host/stromal MMP-3 may have different roles in prostate tumor growth in bone that
tumor-derived MMP-3. Using MMP-3 null mice, we would like to study the impact of
stromal MMP-3 on prostate tumor growth in bone. We could also combine study the
combined effect of total (tumor and stroma) MMP-3 ablation. The addition of these
experiments will enable us to fully understand MMP-3’s activities and utility as a
therapeutic target in prostate to bone metastases.
The biochemical understanding of MMPs has improved and we can now better
target individual MMPs based on their active sites, sub site pockets, secondary
substrate binding exosites, and even some non-catalytic activities [269, 272]. Applying
mechanism based targeting approaches has led to the development of modern highly
selective MMP inhibitors.
developed

to

The ability to selectively target MMPs is being further

incorporate

strategies

that

allow

tissue

specific

inhibition.

Bisphosphonates specifically target bone due to their affinity for hydroxyapatite and
have been used clinically to treat skeletal malignancy for several years [90, 399]. Work
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from our lab and colleagues at the University of Bari to chemically modify
bisphosphonates by attaching an MMP inhibiting moiety to create “dual inhibitors” has
shown promising preclinical results in in vivo 4T1 and PyMT-R221A bone metastatic
breast cancer models [123, 124]. Despite the fact that MMP-3 may not be the best
MMP for inhibition, these strategies will be important for the MMP field in allowing the
selective inhibition of predominantly pro-tumorigenic MMPs like MMP-2.

Table 4-1. Experimental Therapies for Metastatic Prostate Cancer

Drug Name

Target

Action

Trial Results

Orteronel

CYP17A1 (17,20
lyase activity)

Reduces
circulating
testosterone levels

Decreased
number of CTCs,
improved
radiographic PFS

[400, 401]

Ipilimumab

CTLA-4

T-cell activation

Ongoing

[402, 403]

Nivolumab

PD-1

T-cell activation

Ongoing

[404]

Prostvac-VF

Delivery of PSA
transgene

T-cell activation

Cabozantinib

c-MET, VEGF-R2

Inhibits tyrosine
kinase activity

Tasquinomod

Thrombospondin
S100A9

Anti-angiogenic,
reduces MDSC
recruitment

Custirsen

Clusterin

Improves
docetaxel
response

Improved median
survival
Partial resolution
of bone lesions,
decreased number
of CTCs,
decreased pain
Improved median
PFS, stable bone
alkaline
phosphatase
levels
Extended median
survival, extended
PFS, improved
PSA declines

Reference

[85, 405]

[406]

[407]

[408]

Only within the last decade have therapies that extend overall survival for men
with metastatic prostate cancer become FDA approved. Many of these approved
therapies as well as therapies under current investigation (Table 4-1) have shifted focus
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away from traditional approaches such as chemotherapy and androgen inhibitors which
solely target the cancer cells and instead consider the tumor microenvironment. The
most recent agent to receive FDA approval for mCRPC is radium-223 [97]. The bone
seeking properties of radium-223 as well as other radiopharmaceuticals make them
particularly useful in the treatment of bone metastases. In a study of men with mCRPC
previously treated with radiotherapy, radium-223 showed improved overall survival, time
to PSA progression, and reduced alkaline phosphatase levels (measure of bone
remodeling). In addition, radium-223 also delayed the time to first SRE [99]. Previous
radiopharmaceuticals used to treat mCRPC were only effective at reducing pain,
therefore, radium-223 represents an important leap forward for the field [97].
Understanding the roles for MMPs and their interaction with other factors in the vicious
cycle as well as the development of selective MMP inhibitors will continue to generate
novel methods to control metastasis.
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